<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Microbiol</journal-id><journal-id journal-id-type="iso-abbrev">Front Microbiol</journal-id><journal-id journal-id-type="pmc-domain-id">1526</journal-id><journal-id journal-id-type="pmc-domain">frontmicrobio</journal-id><journal-id journal-id-type="publisher-id">Front. Microbiol.</journal-id><journal-title-group><journal-title>Frontiers in Microbiology</journal-title></journal-title-group><issn pub-type="epub">1664-302X</issn><publisher><publisher-name>Frontiers Media SA</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10764465</article-id><article-id pub-id-type="pmcid-ver">PMC10764465.1</article-id><article-id pub-id-type="pmcaid">10764465</article-id><article-id pub-id-type="pmcaiid">10764465</article-id><article-id pub-id-type="pmid">38179453</article-id><article-id pub-id-type="doi">10.3389/fmicb.2023.1249718</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Microbiology</subject><subj-group><subject>Mini Review</subject></subj-group></subj-group></article-categories><title-group><article-title>TLR agonists as vaccine adjuvants in the prevention of viral infections: an overview</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Kayesh</surname><given-names initials="MEH">Mohammad Enamul Hoque</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="c001" ref-type="corresp">
<sup>*</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1413356/overview"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kohara</surname><given-names initials="M">Michinori</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/18249/overview"/></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Tsukiyama-Kohara</surname><given-names initials="K">Kyoko</given-names></name><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="c002" ref-type="corresp">
<sup>*</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/505142/overview"/></contrib></contrib-group><aff id="aff1"><sup>1</sup><institution>Department of Microbiology and Public Health, Faculty of Animal Science and Veterinary Medicine, Patuakhali Science and Technology University</institution>, <addr-line>Barishal</addr-line>, <country>Bangladesh</country></aff><aff id="aff2"><sup>2</sup><institution>Department of Microbiology and Cell Biology, Tokyo Metropolitan Institute of Medical Science</institution>, <addr-line>Tokyo</addr-line>, <country>Japan</country></aff><aff id="aff3"><sup>3</sup><institution>Transboundary Animal Diseases Centre, Joint Faculty of Veterinary Medicine, Kagoshima University</institution>, <addr-line>Kagoshima</addr-line>, <country>Japan</country></aff><author-notes><fn fn-type="edited-by" id="fn0001"><p>Edited by: Gaurav Joshi, Texas Tech University, United States</p></fn><fn fn-type="edited-by" id="fn0002"><p>Reviewed by: Ambuj Shrivastava, Defence Research and Development Establishment (DRDE), India; Mohsan Ullah Goraya, Huaqiao University, China</p></fn><corresp id="c001">*Correspondence: Mohammad Enamul Hoque Kayesh, <email>mehkayesh@pstu.ac.bd</email></corresp><corresp id="c002">Kyoko Tsukiyama-Kohara, <email>kkohara@vet.kagoshima-u.ac.jp</email></corresp></author-notes><pub-date pub-type="epub"><day>21</day><month>12</month><year>2023</year></pub-date><pub-date pub-type="collection"><year>2023</year></pub-date><volume>14</volume><issue-id pub-id-type="pmc-issue-id">427262</issue-id><elocation-id>1249718</elocation-id><history><date date-type="received"><day>12</day><month>7</month><year>2023</year></date><date date-type="accepted"><day>01</day><month>12</month><year>2023</year></date></history><pub-history><event event-type="pmc-release"><date><day>21</day><month>12</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>04</day><month>01</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-01-29 22:25:10.213"><day>29</day><month>01</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2023 Kayesh, Kohara and Tsukiyama-Kohara.</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Kayesh, Kohara and Tsukiyama-Kohara</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="fmicb-14-1249718.pdf"/><abstract><p>Tol-like receptor (TLR) agonists, as potent adjuvants, have gained attention in vaccine research for their ability to enhance immune responses. This study focuses on their application in improving vaccine efficacy against key viral infections, including hepatitis B virus (HBV), hepatitis C virus (HCV), human immunodeficiency virus (HIV), SARS-CoV-2, influenza virus, and flaviviruses, including West Nile virus, dengue virus, and chikungunya virus. Vaccines are crucial in preventing microbial infections, including viruses, and adjuvants play a vital role in modulating immune responses. However, there are still many diseases for which effective vaccines are lacking or have limited immune response, posing significant threats to human health. The use of TLR agonists as adjuvants in viral vaccine formulations holds promise in improving vaccine effectiveness. By tailoring adjuvants to specific pathogens, such as HBV, HCV, HIV, SARS-CoV-2, influenza virus, and flavivirus, protective immunity against chronic and emerging infectious disease can be elicited.</p></abstract><kwd-group><kwd>TLR</kwd><kwd>hepatitis virus</kwd><kwd>HIV</kwd><kwd>SARS-CoV-2</kwd><kwd>influenza virus</kwd></kwd-group><funding-group><funding-statement>The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was supported by grants from the Tokyo Metropolitan government and Japan agency for medical research and development (22582594).</funding-statement></funding-group><counts><fig-count count="1"/><table-count count="2"/><equation-count count="0"/><ref-count count="133"/><page-count count="11"/><word-count count="10696"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta><custom-meta><meta-name>section-at-acceptance</meta-name><meta-value>Virology</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1"><title>Introduction</title><p>Viral infections pose a significant threat to human health, and while vaccines exist for many viruses, there are still numerous viruses without approved vaccines. Additionally, the limited treatment options for viral infections, as antibiotics are ineffective against viruses, further highlight the importance of viral vaccines in prevention. Developing safe and efficient vaccines to combat viral infections is of utmost importance. Adjuvants, substances used in vaccines to stimulate and enhance immune response, have gained significant research interest for improving vaccine effectiveness and durability (<xref rid="ref100" ref-type="bibr">Pulendran and O'hagan, 2021</xref>).</p><p>The innate immune system is a key component of host immunity that plays a significant role in the host defense against invading pathogens, including viruses (<xref rid="ref91" ref-type="bibr">Medzhitov and Janeway, 2000</xref>). Germ-line encoded pattern recognition receptors (PRRs), including Toll-like receptors (TLRs), nucleotide oligomerization domain (NOD)-like receptors (NLRs), and retinoic acid-inducible gene-I (RIG-I)-like receptors (RLRs) recognize conserved structures of microbes, which are known as pathogen-associated molecular patterns (PAMPs), directly activate immune cells (<xref rid="ref65" ref-type="bibr">Kawai and Akira, 2009</xref>; <xref rid="ref92" ref-type="bibr">Mogensen, 2009</xref>; <xref rid="ref124" ref-type="bibr">Wicherska-Pawlowska et al., 2021</xref>). TLRs are transmembrane receptors that can be found both on the cell surface and in intracellular membranes, and NLRs and RLRs are intracellular receptor molecules (<xref rid="ref124" ref-type="bibr">Wicherska-Pawlowska et al., 2021</xref>). Along with TLRs, NLRs and RLRs also play significant role in the recognition of different viruses, including hepatitis B virus (HBV), hepatitis C virus (HCV), influenza virus, human immunodeficiency virus (HIV), Zika virus, measles virus, etc. and subsequently cause innate immune activation for shaping adaptive immunity (<xref rid="ref62" ref-type="bibr">Kato et al., 2006</xref>; <xref rid="ref124" ref-type="bibr">Wicherska-Pawlowska et al., 2021</xref>).</p><p>Toll-like receptors (TLRs) are the best studied PRRs, playing a key role in sensing PAMPs and induce immune responses that shape adaptive immunity (<xref rid="ref57" ref-type="bibr">Janeway and Medzhitov, 2002</xref>; <xref rid="ref71" ref-type="bibr">Kayesh et al., 2021c</xref>). To date, 10 TLRs (TLR1&#8211;TLR10) have been identified in humans, and 13 in mice, and different studies have revealed their respective TLR ligands (<xref rid="ref111" ref-type="bibr">Takeda and Akira, 2005</xref>). Respective TLR agonist can activate specific TLR signaling, and following recognition of ligands, TLRs recruit adapter molecules such as myeloid differentiation primary response protein 88 (MyD88), TIR domain-containing adapter protein (TIRAP)/MyD88 adaptor&#8211;like protein (MAL), Toll&#8211;IL-1&#8211;resistance (TIR) domain-containing adapter inducing IFN-&#946; (TRIF; also known as TICAM1) and TRIF-related adapter molecule (TRAM; also known as TICAM2) culminate in the activation of nuclear factor (NF)-&#954;B or interferon (IFN) regulatory factor (IRF), regulating immunomodulation (<xref rid="ref111" ref-type="bibr">Takeda and Akira, 2005</xref>; <xref rid="ref64" ref-type="bibr">Kawai and Akira, 2006</xref>; <xref rid="fig1" ref-type="fig">Figure 1</xref>). MyD88 is the common downstream adaptor recruited by all TLRs, except for TLR3 (<xref rid="ref112" ref-type="bibr">Takeuchi et al., 2000</xref>; <xref rid="fig1" ref-type="fig">Figure 1</xref>). TLRs activate multiple steps in the induction of inflammatory reactions toward eliminating the invading pathogens and help in the systemic defense (<xref rid="ref56" ref-type="bibr">Iwasaki and Medzhitov, 2004</xref>). A strong activation of the innate immune system is important for maturation and activation of immune cells as well as production of cytokines and chemokines to induce a potent adaptive immune response (<xref rid="ref32" ref-type="bibr">Edwards et al., 2017</xref>). Moreover, TLRs play role in multiple dendritic cell functions and induce signals that are critical for initiation of the adaptive immune responses (<xref rid="ref56" ref-type="bibr">Iwasaki and Medzhitov, 2004</xref>). For further details on TLR signaling that culminate in the production of cytokines/chemokines, please see other published reviews (<xref rid="ref64" ref-type="bibr">Kawai and Akira, 2006</xref>; <xref rid="ref18" ref-type="bibr">Brown et al., 2011</xref>; <xref rid="ref30" ref-type="bibr">Duan et al., 2022</xref>).</p><fig position="float" id="fig1" orientation="portrait"><label>Figure 1</label><caption><p>An overall mechanism of activation of TLR with respective TLR agonist.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fmicb-14-1249718-g001.jpg"/></fig><p>Numerous investigations are currently underway to develop an effective adjuvant system using TLR agonists to enhance vaccine efficacy (<xref rid="ref29" ref-type="bibr">Dowling, 2018</xref>; <xref rid="ref69" ref-type="bibr">Kayesh et al., 2021a</xref>,<xref rid="ref71" ref-type="bibr">c</xref>; <xref rid="ref100" ref-type="bibr">Pulendran and O'hagan, 2021</xref>). TLRs are a family of type I transmembrane receptors containing three domains: an N-terminal extracellular leucine-rich repeat domain that recognizes specific PAMPs, a single transmembrane domain, and an intracellular Toll-interleukin 1 receptor (TIR) domain required for downstream signal transduction (<xref rid="ref66" ref-type="bibr">Kawai and Akira, 2010</xref>).</p><p>Agonists come from a variety of sources, both natural and synthetic, and specific natural ligands have been identified for different TLRs. Examples include lipoproteins and peptidoglycans for TLR2, double-stranded RNA of viral origin for TLR3, bacterial lipopolysaccharide (LPS) and lipoteichoic acid for TLR4, bacterial flagellin for TLR5, single-stranded RNA for TLR7 and TLR8, unmethylated CpG motifs found in bacterial DNA or viruses for TLR9, and viral protein/viral RNP complexes for TLR10 (<xref rid="ref122" ref-type="bibr">Weeratna et al., 2005</xref>; <xref rid="ref75" ref-type="bibr">Lee et al., 2014</xref>; <xref rid="ref15" ref-type="bibr">Bezemer and Garssen, 2020</xref>; <xref rid="ref38" ref-type="bibr">Fore et al., 2020</xref>). Synthetic TLR agonists, developed by mimicking the molecular patterns and the immunostimulatory activities of their natural ligands, have been investigated for specific applications (<xref rid="ref129" ref-type="bibr">Yang et al., 2022</xref>). Synthetic TLR agonists, such as Pam<sub>3</sub>CSK<sub>3</sub> for TLR2 and TLR6, Poly I:C for TLR3, monophosphoryl lipid A (MPLA) for TLR4, imidazoquinoline-like molecules, imiquimod (R-837), resiquimod (R-848), S-27609, and guanosine analogs (e.g., loxoribine) for TLR7/8, as well as unmethylated CpG DNA for TLR9, have been reported (<xref rid="ref45" ref-type="bibr">Gorden et al., 2005</xref>; <xref rid="ref60" ref-type="bibr">Kaczanowska et al., 2013</xref>).</p><p>Cyclic dinucleotides (CDNs), including cyclic di-adenosine monophosphate, cyclic di-guanosine monophosphate, cyclic GMP-AMP (cGAMP) are ubiquitous small molecule second messengers synthesized by bacteria, which can activate different immune pathways, including the stimulator of interferon genes (STING; <xref rid="ref31" ref-type="bibr">Dubensky et al., 2013</xref>; <xref rid="ref44" ref-type="bibr">Gogoi et al., 2020</xref>). CDNs have been used as a relatively new class of vaccine adjuvants in many vaccine formulations, and shown to increase potency of bacterial vaccines (<xref rid="ref96" ref-type="bibr">Ogunniyi et al., 2008</xref>; <xref rid="ref51" ref-type="bibr">Hu et al., 2009</xref>; <xref rid="ref128" ref-type="bibr">Yan et al., 2009</xref>). In addition, it has been shown that CDNs-adjuvanted subunit vaccine can elicit both Th1 and Th17 immune response, providing long-lasting protective immunity to <italic toggle="yes">Mycobacterium tuberculosis</italic> in mouse model (<xref rid="ref116" ref-type="bibr">Van Dis et al., 2018</xref>). Therefore, the investigation of CDNs as an adjuvant in the viral vaccines could also be promising.</p><p>For an effective immunization approach, an effective vaccine is required, capable of generating long-lasting high titers of neutralizing antibodies with minimal antigen content. An important factor in meeting these requirements is the selection of an appropriate adjuvant. Until recently, alum was the only adjuvant approved for human use in the United States (<xref rid="ref11" ref-type="bibr">Baylor et al., 2002</xref>). However, in 2009, the U.S. Food and Drug Administration granted licensure for human use to the first TLR ligand-vaccine, a TLR4 agonist-adjuvanted human papillomavirus vaccine (<xref rid="ref20" ref-type="bibr">Centers for Disease Control and Prevention, 2010</xref>). Accordingly, numerous studies are focused on developing vaccines with novel adjuvant formulations for refining or developing vaccines against various infections (<xref rid="ref101" ref-type="bibr">Reed et al., 2013</xref>).</p><p>Notably, the selection of an appropriate vaccine adjuvant is critical for effective vaccine efficacy, which plays an important role in augmenting the immune response against particular pathogens (<xref rid="ref101" ref-type="bibr">Reed et al., 2013</xref>). Although actual mechanisms of adjuvants remain poorly understood, several potential mechanisms have been proposed, including the formation of depots for slow antigen release, activation of immune cells and antigen processing, and induction of cytokines and chemokines, all of which contribute to enhancing vaccine effectiveness (<xref rid="ref10" ref-type="bibr">Awate et al., 2013</xref>). Adjuvants can influence vaccine response through various means, such as increasing functional antibody titers, increasing effector T cells, facilitating the rapid induction of protective responses, reducing antigen dosage and number of injections, enhancing memory and persistence (B and T cells), boosting responses in the immunocompromised individual, and broadening the scope of the immune response (<xref rid="ref85" ref-type="bibr">Maisonneuve et al., 2014</xref>).</p><p>In modern vaccines, subunit components of pathogens are frequently used for vaccine preparation instead of employing whole, killed, or attenuated pathogens. However, this approach may reduce immunogenicity, requiring vaccine adjuvants to be incorporated with the antigens to enhance the immune response (<xref rid="ref82" ref-type="bibr">Luchner et al., 2021</xref>). Aluminum-containing adjuvants, the first human vaccine adjuvants approved in clinical use, induce strong humoral immunity but do not equally stimulate cellular immunity, rendering them ineffective against intracellular virus infections (<xref rid="ref55" ref-type="bibr">Igietseme et al., 2004</xref>; <xref rid="ref97" ref-type="bibr">Oleszycka et al., 2018</xref>; <xref rid="ref120" ref-type="bibr">Wang and Xu, 2020</xref>). There is an increasing interest in the use of TLR agonists as immunomodulators that can influence the outcome of treatment of infection (<xref rid="ref69" ref-type="bibr">Kayesh et al., 2021a</xref>,<xref rid="ref71" ref-type="bibr">c</xref>; <xref rid="ref59" ref-type="bibr">Jimenez-Leon et al., 2023</xref>). TLR agonists have shown high potency in activating innate immunity in a number of vaccine adjuvants and immunomodulatory agents against infectious diseases and cancers (<xref rid="ref82" ref-type="bibr">Luchner et al., 2021</xref>). The use of TLR agonists as vaccine adjuvants remains the current focus of research aimed at increasing vaccine efficacy. In this study, we review the progress and useability of TLR agonists as vaccine adjuvants in different viral vaccines, particular focusing on hepatitis B virus (HBV) and SARS-CoV-2 vaccines, and other vaccines, including hepatitis C virus (HCV), human immunodeficiency virus (HIV), influenza virus, and flavivirus [dengue virus (DENV), West Nile virus (WNV), Chikungunya virus (CHIKV)] vaccines.</p></sec><sec id="sec2"><title>Prospects of TLR agonists in viral vaccines</title><p>TLR agonists are extensively studied as adjuvants to enhance vaccines effectiveness (<xref rid="ref100" ref-type="bibr">Pulendran and O'hagan, 2021</xref>). These agonists have gained significant attention as potent immunomodulators capable of inducing the production of IFN, proinflammatory cytokines, and chemokines. They show promise against various viral infections, including HBV, HCV, HIV-1, influenza virus, and SARS-CoV-2 (<xref rid="ref87" ref-type="bibr">Martinsen et al., 2020</xref>; <xref rid="ref69" ref-type="bibr">Kayesh et al., 2021a</xref>,<xref rid="ref71" ref-type="bibr">c</xref>, <xref rid="ref72" ref-type="bibr">2022</xref>, <xref rid="ref73" ref-type="bibr">2023</xref>; <xref rid="ref59" ref-type="bibr">Jimenez-Leon et al., 2023</xref>; <xref rid="ref130" ref-type="bibr">Yin et al., 2023</xref>). However, further studies are needed to identify potential TLR agonists for vaccine adjuvants. For example, a recent study compared three TLR agonists [TLR1/2 (Pam3Cys), TLR7/8 (R848), or TLR9 (CpG ODN)] as vaccine adjuvants in combination with inactivated porcine reproductive and respiratory syndrome virus (iPRRSV). The study found no detectable antigen-specific immune response after intramuscular (i.m.) or subcutaneous vaccination. However, a non-antigen-specific IFN-&#947; production was observed by the TLR9 agonist group, which reduced viremia upon challenge compared to that in the non-vaccinated animals (<xref rid="ref118" ref-type="bibr">Vreman et al., 2019</xref>).</p><p>The development of effective peptide and DNA vaccines is hindered by poor immunogenicity. To address this challenge, researchers are exploring novel adjuvants, including TLR agonists, which offer immunomodulating and immunotherapeutic effects (<xref rid="ref109" ref-type="bibr">Surendran et al., 2018</xref>; <xref rid="ref94" ref-type="bibr">Mullins et al., 2019</xref>). TLR stimulation mediates T<sub>H</sub>1 and T<sub>H</sub>17 immune responses (<xref rid="ref3" ref-type="bibr">Agrawal et al., 2003</xref>), and the synergistic activation of TLRs and NLRs has been reported to elicit these immune responses (<xref rid="ref39" ref-type="bibr">Fritz et al., 2007</xref>; <xref rid="ref83" ref-type="bibr">Magalhaes et al., 2008</xref>, <xref rid="ref84" ref-type="bibr">2011</xref>). The increasing understanding of TLR agonists has captured the attention of vaccinologists (<xref rid="ref29" ref-type="bibr">Dowling, 2018</xref>), and the COVID-19 pandemic further accelerated clinical research on vaccines incorporating TLR agonist-based adjuvants (<xref rid="ref129" ref-type="bibr">Yang et al., 2022</xref>). The inclusion of TLR agonists in vaccine development holds promise for enhancing vaccine efficacy.</p></sec><sec id="sec3"><title>TLR agonists as vaccine adjuvants in HBV vaccines</title><p>Despite the availability of an effective preventive vaccine for HBV, chronic HBV infection remains a global health problem (<xref rid="ref35" ref-type="bibr">Ezzikouri et al., 2020</xref>). According to the World Health Organization (WHO), an estimated 296 million people were affected by chronic HBV infection in 2019, with 1.5 million new infections occurring annually (<xref rid="ref126" ref-type="bibr">World Health Organization, 2022</xref>). While the currently available recombinant HBV vaccines demonstrate excellent safety and immunogenicity (<xref rid="ref8" ref-type="bibr">Assad and Francis, 1999</xref>), they still face challenges in inducing protective immunity in poor vaccine responders, including immunocompromised people, older adults, diabetics, and those with chronic kidney disease (<xref rid="ref76" ref-type="bibr">Lee and Lim, 2021</xref>).</p><p>Immune tolerance poses a significant obstacle in the cure of HBV infection (<xref rid="ref114" ref-type="bibr">Tran, 2011</xref>). The mechanism behind immune tolerance is not well understood, but HBV-specific T-cell hyporesponsiveness may impair antigen processing and transport to major histocompatibility complex class I molecules (<xref rid="ref108" ref-type="bibr">Sukriti et al., 2010</xref>). In an investigation of overcoming HBsAg-specific immune tolerance state in humanized mice model, immunization with CL097 (TLR7/8 agonist)-conjugated HBV-Ag was found to reverse immune tolerance in HBV-Tg mice, and induced antigen-specific immune responses (<xref rid="ref119" ref-type="bibr">Wang et al., 2014</xref>). TLR7/8 agonists demonstrated potent adjuvant properties in inducing antigen-specific Th1 responses in an immune tolerant state (<xref rid="ref119" ref-type="bibr">Wang et al., 2014</xref>). In the woodchuck model of chronic HBV, GS-9688, an oral selective small molecule agonist of TLR8, effectively reduced serum viral load by over five logs and also suppressed woodchuck hepatitis surface antigen in 50% of treated woodchucks (<xref rid="ref24" ref-type="bibr">Daffis et al., 2021</xref>). Another study showed that GS-9688 induced cytokines in human peripheral blood mononuclear cells, leading to the activation of antiviral effector function by increasing the frequency of HBV-specific CD8+ T cells, CD4+ follicular helper T cells, NK cells, and mucosal-associated invariant T cells (<xref rid="ref5" ref-type="bibr">Amin et al., 2021</xref>). In our previous study, we observed that HBV infection in tree shrew model could induce a significant suppression of IFN-&#946; response at 31&#8201;weeks post-infection, contributing to the chronicity (<xref rid="ref67" ref-type="bibr">Kayesh et al., 2017a</xref>). In addition, no induction of TLR3 and suppression of TLR9 was found (<xref rid="ref67" ref-type="bibr">Kayesh et al., 2017a</xref>).</p><p>HEPLISAV-B is a recombinant HBV vaccine composed of HBsAg combined with the CpG 1,018 adjuvant, which stimulates innate immunity through TLR9 (<xref rid="ref76" ref-type="bibr">Lee and Lim, 2021</xref>). In a Phase III clinical trial, HEPLISAV-B demonstrated the ability to rapidly and consistently produce high titers of sustained seroprotection with fewer immunizations, including in individuals with poor response to vaccination (<xref rid="ref33" ref-type="bibr">Eng et al., 2013</xref>). Compared to Engerix-B, HEPLISAV-B has shown superior and earlier seroprotection, while maintaining a favorable profile (<xref rid="ref76" ref-type="bibr">Lee and Lim, 2021</xref>). Notably, HEPLISAV-B was found to induce higher seroprotection rates in the poor vaccine responders such older adults, diabetics, and those with chronic kidney disease, surpassing the effectiveness of Engerix-B (<xref rid="ref76" ref-type="bibr">Lee and Lim, 2021</xref>). This suggests that HEPLISAV-B is more efficacious in these individuals. Historically, persons living with HIV (PLWH) have exhibited poor responses to HBV vaccination, with low seroprotection rates ranging from 35% to 70% following a 3-dose series. However, according to a press release regarding the study findings of an ongoing phase 3 clinical trial (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://ClinicalTrials.gov" ext-link-type="uri">ClinicalTrials.gov</ext-link>, ID: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04193189">NCT04193189</ext-link>) presented by the National Institute of Allergy and Infectious Diseases (NIAID), HEPLISAV-B, an HBV vaccine containing recombinant HB surface antigen and a CpG-based TLR9 agonist, has been found to be effective in protecting adults living with HIV who have never been vaccinated against or infected with HBV (<xref rid="ref95" ref-type="bibr">National Institutes of Health, 2022</xref>).</p><p>Adjuvant System 04 (AS04) combines aluminum hydroxide with the TLR4 agonist 3-O-desacyl-4&#8242;-monophosphoryl lipid A (<xref rid="ref26" ref-type="bibr">Didierlaurent et al., 2009</xref>). FENDrix (GlaxoSmithKline Biologicals), an adjuvanted HBV vaccine consists of recombinant HBsAg formulated with aluminum phosphate and MPL, a purified, detoxified derivative of the lipopolysaccharide molecule found in the bacterial wall of <italic toggle="yes">Salmonella minnesota</italic> (<xref rid="ref40" ref-type="bibr">Garcon et al., 2007</xref>). This vaccine has been investigated for its ability to elicit a better immune response. FENDrix is administered in a four-dose scheme: on day 0, month 1, month 2, and month 6 (after day 0). Due to the improved adjuvant system, FENDrix induces higher concentrations of protective antibodies more rapidly (<xref rid="ref74" ref-type="bibr">Kundi, 2007</xref>). In a prospective cohort study, HB-AS04 showed a higher efficacy in patients on maintenance dialysis, although a significant number of non-responders were still present (<xref rid="ref37" ref-type="bibr">Fabrizi et al., 2015</xref>). Another open-label, non-randomized trial showed the persistence of anti-HBs antibody among responder patients during a long follow-up period (<xref rid="ref36" ref-type="bibr">Fabrizi et al., 2020</xref>). In a multicenter phase 3 comparative study involving adults receiving hemodialysis who had previously received HBV vaccination but were not seroprotected, a booster dose of HEPLISAV-B was found to induce a higher seroprotection rate (52.8%; 95% confidence interval [CI]: 38.6, 66.7%) compared to Engerix-B (32.6%; 95% CI: 19.5, 48.0%) and FENDrix (43.1%; 95% CI: 29.3, 57.8%) recipients (<xref rid="ref42" ref-type="bibr">Girndt et al., 2022</xref>).</p><p>HIV/HBV co-infection may lead to increased morbidity and mortality compared to HBV or HIV mono-infection (<xref rid="ref123" ref-type="bibr">Whitaker et al., 2012</xref>; <xref rid="ref73" ref-type="bibr">Kayesh et al., 2023</xref>). Although the immunogenicity of HBV vaccines is impaired in HIV-infected patients (<xref rid="ref25" ref-type="bibr">de Vries-Sluijs et al., 2020</xref>), immunization with a HBV vaccine is the most effective way to prevent infection in people with HIV. To enhance the vaccine response in immunocompromised individuals, new strategies are needed, such as the addition of new adjuvants or increased vaccine doses (<xref rid="ref123" ref-type="bibr">Whitaker et al., 2012</xref>; <xref rid="ref19" ref-type="bibr">Catherine and Piroth, 2017</xref>). A randomized controlled trial in HIV-infected patients revealed an insignificant (<italic toggle="yes">p</italic>&#8201;=&#8201;0.09) increase in anti-HBs&#8201;&#8805;&#8201;10&#8201;IU/L response rate at week 28 following FENDrix (85.7%) and Engerix (65.0%) vaccination (<xref rid="ref25" ref-type="bibr">de Vries-Sluijs et al., 2020</xref>). Notably, a recent multicenter open-label study of TLR9 agonist-adjuvanted HEPLISAV-B vaccine in HIV-positive individuals without prior HBV vaccination found that all 68 participants achieved HBV seroprotective titers after the 3-dose series in the primary analysis, with no unexpected safety concerns (<xref rid="ref86" ref-type="bibr">Marks et al., 2023</xref>). These findings highlight the increased immunogenicity of HBV vaccines and the immunomodulator potential of TLR agonists in enhancing vaccination efficacy. The TLR agonist adjuvants currently under development for HBV vaccines are listed in <xref rid="tab1" ref-type="table">Table 1</xref>.</p><table-wrap position="float" id="tab1" orientation="portrait"><label>Table 1</label><caption><p>TLR agonists as vaccine adjuvants in HBV vaccines.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top" rowspan="1" colspan="1">Vaccine name</th><th align="left" valign="top" rowspan="1" colspan="1">Sponsor/company</th><th align="left" valign="top" rowspan="1" colspan="1">TLR agonist adjuvant</th><th align="left" valign="top" rowspan="1" colspan="1">Target TLR</th><th align="left" valign="top" rowspan="1" colspan="1">Clinical phase</th><th align="left" valign="top" rowspan="1" colspan="1">Disease target</th><th align="left" valign="top" rowspan="1" colspan="1">Effects on host immunity</th><th align="left" valign="top" rowspan="1" colspan="1">Clinical Trials. Gov identifier/reference</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">HEPLISAV-B</td><td align="left" valign="top" rowspan="1" colspan="1">Dynavax Technologies Corporation</td><td align="left" valign="top" rowspan="1" colspan="1">CpG 1,018</td><td align="left" valign="top" rowspan="1" colspan="1">TLR9</td><td align="left" valign="top" rowspan="1" colspan="1">Phase III</td><td align="left" valign="top" rowspan="1" colspan="1">Hepatitis B</td><td align="left" valign="top" rowspan="1" colspan="1">Strongly favors development of the Th1 subset of helper T cells</td><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="ref54" ref-type="bibr">Hyer and Janssen (2018)</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HEPLISAV-B</td><td align="left" valign="top" rowspan="1" colspan="1">Dynavax Technologies Corporation</td><td align="left" valign="top" rowspan="1" colspan="1">CpG 1,018</td><td align="left" valign="top" rowspan="1" colspan="1">TLR9</td><td align="left" valign="top" rowspan="1" colspan="1">Phase III</td><td align="left" valign="top" rowspan="1" colspan="1">Hepatitis B (HIV coinfection)</td><td align="left" valign="top" rowspan="1" colspan="1">Induces seroprotective titers in all participants with HIV without prior HBV vaccination</td><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="ref86" ref-type="bibr">Marks et al. (2023)</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HBV-AS04</td><td align="left" valign="top" rowspan="1" colspan="1">GlaxoSmithKline</td><td align="left" valign="top" rowspan="1" colspan="1">Monophosphoryl-Lipid A (MPLA)</td><td align="left" valign="top" rowspan="1" colspan="1">TLR4</td><td align="left" valign="top" rowspan="1" colspan="1">Phase III</td><td align="left" valign="top" rowspan="1" colspan="1">Hepatitis B</td><td align="left" valign="top" rowspan="1" colspan="1">Improves seroresponse</td><td align="left" valign="top" rowspan="1" colspan="1"><xref rid="ref37" ref-type="bibr">Fabrizi et al. (2015</xref>, <xref rid="ref36" ref-type="bibr">2020)</xref></td></tr></tbody></table></table-wrap></sec><sec id="sec4"><title>TLR agonists as vaccine adjuvants in HCV vaccines</title><p>HCV causes chronic liver infection and is a leading cause of liver cancer. According to the WHO, 58 million people worldwide are chronically infected with HCV, with an annual approximately 1.5 million new infections [<xref rid="ref127" ref-type="bibr">World Health Organization (WHO), 2022</xref>]. Although newly approved direct-acting antivirals (DAAs) have shown great therapeutic success for HCV infection (<xref rid="ref77" ref-type="bibr">Li and De Clercq, 2017</xref>), DAA therapy is costly and often results in side effects, limiting its accessibility to patients. Notably, DAA therapy has been associated with an increasing risk of hepatocellular carcinoma (HCC) in patients treated with DAAs (<xref rid="ref21" ref-type="bibr">Chinchilla-Lopez et al., 2017</xref>; <xref rid="ref110" ref-type="bibr">Tajiri et al., 2022</xref>). Currently, there is no licensed protective vaccine against HCV, making the development of an effective preventive vaccine is critical (<xref rid="ref12" ref-type="bibr">Behmard et al., 2022</xref>).</p><p>Scientists are diligently working on different strategies to develop an effective HCV vaccine. Immunoinformatics-based multi-epitope constructs, along with the use of TLR3 and TLR4 agonists, have shown immunogenicity, non-allergenicity, and non-toxicity (<xref rid="ref12" ref-type="bibr">Behmard et al., 2022</xref>), requiring further investigation into the protective traits and safety of these designed candidates. The improved efficacy of HCV vaccine candidates due to TLR agonists has been reported in several studies. In a phase 1 study, TLR9 agonist CpG 10,101 was found to dose-dependently increase immune marker activation while simultaneously decreasing HCV RNA levels (<xref rid="ref90" ref-type="bibr">McHutchison et al., 2007</xref>), supporting the future exploration of CpG 10,101 as a vaccine adjuvant for HCV candidates. Furthermore, including TLR7 and TLR9 agonists in HCV vaccine candidates has been shown to promote the maturation of plasmacytoid dendritic cells, leading to improved antigen presentation and enhanced viral immunization (<xref rid="ref27" ref-type="bibr">Dominguez-Molina et al., 2018</xref>). In an earlier study, an induction of TLR3, TLR7 and TLR8 mRNA was observed in HCV-infected tree shrew liver, compared to uninfected liver tissues (<xref rid="ref68" ref-type="bibr">Kayesh et al., 2017b</xref>).</p><p>HCV virus-like particle (VLP)-based vaccines adjuvanted with TLR2 agonist Pam(2)Cys [E(8)Pam(2)Cys] induced significant HCV-LP and E2-specific antibody responses mice. In comparison to traditionally alum-adjuvanted VLPs, a single dose of VLPs formulated with this lipopeptide achieved antibody titers equivalent to those obtained with up to three doses of traditionally alum-adjuvanted VLPs (<xref rid="ref22" ref-type="bibr">Chua et al., 2012</xref>).</p></sec><sec id="sec5"><title>TLR agonists as vaccine adjuvants in HIV vaccines</title><p>Developing a HIV-1 vaccine that can generate high titers of functional antibodies against HIV-1 remains a high priority. Single or combined effect of TLR agonists is now also being investigated for the development of TLR agonist-adjuvanted HIV-1 vaccines (<xref rid="ref93" ref-type="bibr">Moody et al., 2014</xref>; <xref rid="ref102" ref-type="bibr">Rozman et al., 2023</xref>). It has been shown that HIV Gag protein conjugated to TLR7/8 agonist (3&#8201;M-012) could enhance the magnitude of Th1 and CD8+ T cell responses in nonhuman primates (<xref rid="ref125" ref-type="bibr">Wille-Reece et al., 2005</xref>). In a rhesus macaque model, it has been shown that TLR agonists can enhance epitope-specific HIV-1 Env reactive antibody levels (<xref rid="ref93" ref-type="bibr">Moody et al., 2014</xref>). It was also observed that the combination of TLR7/8 and TLR9 agonists could elicit higher titers of neutralizing and ADCC-mediating antibodies (<xref rid="ref93" ref-type="bibr">Moody et al., 2014</xref>).</p><p>Studies have shown that combining ligands for three TLRs (TLR2/6, TLR3, and TLR9) can increase the production of DC IL-15, promoting DC activation and stimulation of NK cells (<xref rid="ref88" ref-type="bibr">Mattei et al., 2001</xref>; <xref rid="ref6" ref-type="bibr">Anguille et al., 2015</xref>). This combination has also greatly increased the protective efficacy of HIV envelope peptide vaccines in mice models (<xref rid="ref133" ref-type="bibr">Zhu et al., 2010</xref>).</p><p>A recent study reported that intranasal administration of TLR7/NOD2L agonist in conjunction with the NP-p24 HIV vaccine resulted in a potent adjuvant effect, inducing high-quality humoral and adaptive immune responses both in systemic and mucosal compartments (<xref rid="ref48" ref-type="bibr">Gutjahr et al., 2020</xref>). Long-lived plasma cells (LLPCs), primarily residing in the bone marrow, are critical mediators of durable antibody responses (<xref rid="ref79" ref-type="bibr">Liu et al., 2022</xref>). It has been reported that 3&#8201;M-052, a TLR7- and TLR8-agonist adjuvant can induce notably high and persistent (up to ~1&#8201;year) frequencies of Env-specific LLPCs in the bone marrow and serum antibody responses in rhesus macaques (<xref rid="ref61" ref-type="bibr">Kasturi et al., 2020</xref>). A recent study showed that TLR4 agonist-based nanoparticle adjuvant, saponin/MPLA nanoparticles (SMNP) can enhance lymph flow and antigen entry into lymph nodes in animal models (<xref rid="ref106" ref-type="bibr">Silva et al., 2021</xref>). Silva et al. reported that a single dose vaccination with Env trimers combined with SMNP adjuvant could lead to seroconversion in all vaccinated male and female Indian rhesus monkeys (<italic toggle="yes">Macaca mulatta</italic>) with excellent HIV neutralizing antibody titers (<xref rid="ref106" ref-type="bibr">Silva et al., 2021</xref>), whereas previous studies observed little or no Env-specific IgG in non-human primates after single immunizations of HIV Env trimers with various adjuvants, suggesting SMNP as a promising vaccine adjuvant candidate to be used for further studies for clinical use in HIV infection. TLR7, an endosomal receptor and nucleotide-binding oligomerization domain 2 (NOD2), a cytosolic receptor, are widely expressed at mucosal levels, functioning as key innate receptors (<xref rid="ref48" ref-type="bibr">Gutjahr et al., 2020</xref>). It has been reported that chimeric TLR7/NOD2 agonist was highly potent to stimulate DC maturation both <italic toggle="yes">in vitro</italic> and <italic toggle="yes">in vivo</italic>. Intranasal administration of TLR7/NOD2L agonist with NP-p24 HIV vaccine was found effective in inducing both humoral and adaptive immune response in systemic and mucosal compartments (<xref rid="ref48" ref-type="bibr">Gutjahr et al., 2020</xref>).</p></sec><sec id="sec6"><title>TLR agonists as vaccine adjuvants in SARS-CoV-2 vaccine</title><p>Respiratory virus infections, such as SARS-CoV-2, remain a major global human health concern requiring appropriate preventive measures. Despite success in vaccinating populations against SARS-CoV-2 infection, there are still concerns that need to be addressed, such as duration of immunity, efficacy against emerging variants, protection from infection and transmission, and worldwide availability of vaccines (<xref rid="ref9" ref-type="bibr">Atalis et al., 2022</xref>). To tackle these issues related to SARS-CoV-2 infection, the use of TLR agonists as vaccine adjuvants can be investigated. Studies have shown that intranasal administration of the TLR2/6 agonist INNA-051 in ferret model significantly reduced SARS-CoV-2 viral RNA levels in the nose and throat (<xref rid="ref99" ref-type="bibr">Proud et al., 2021</xref>). TLR agonists are potent immunomodulators that can improve and broaden the efficacy and durability of vaccine responses (<xref rid="ref100" ref-type="bibr">Pulendran and O'hagan, 2021</xref>), making them valuable in the development of potent SARS-CoV-2 vaccines.</p><p>Furthermore, SARS-CoV-2 subunit vaccines adjuvanted with TLR4 and RIG-I agonists have demonstrated the ability to induce robust and unique route-specific adaptive immune responses against SARS-CoV-2 (<xref rid="ref9" ref-type="bibr">Atalis et al., 2022</xref>). SARS-CoV-2 spike subunit vaccine adjuvanted with a dual TLR ligand liposome induced robust systemic neutralizing antibodies in a mouse model of COVID-19, and completely protected against a lethal SARS-CoV-2 challenge (<xref rid="ref1" ref-type="bibr">Abhyankar et al., 2021</xref>). Another study reported varying degrees of protection based on different adjuvant platform against SARS-CoV-2 in rhesus macaques. AS37, a TLR7 agonist adsorbed to alum, and AS03, an &#945;-tocopherol-containing oil-in-water emulsion, induced substantial neutralizing antibody titers in rhesus macaque, promoting protective immunity against SARS-CoV-2 (<xref rid="ref7" ref-type="bibr">Arunachalam et al., 2021</xref>). These findings highlight the need for further research to identify an ideal adjuvant for SARS-CoV-2 vaccine.</p><p>A recent study reported that TLR7-nanoparticle (TLR7-NP)-adjuvanted influenza and SARS-CoV-2 subunit vaccines induced broad neutralizing antibodies in a mouse model, which protected against respective multiple viral variants (<xref rid="ref130" ref-type="bibr">Yin et al., 2023</xref>). Importantly, the TLR7-NP adjuvant can induce cross-reactive antibodies targeting both dominant and subdominant epitopes and antigen-specific CD8+ T-cell responses in mice (<xref rid="ref130" ref-type="bibr">Yin et al., 2023</xref>). Intranasal vaccination with CpG nanoparticle-adjuvanted HA influenza vaccine has been shown to increase protective efficacies in mice (<xref rid="ref28" ref-type="bibr">Dong et al., 2022</xref>). Comparatively, PEI-HA/CpG nanoparticles generated more robust and balanced IgG1/IgG2a neutralizing antibody responses and Fc-mediated antibody-dependent cellular cytotoxicity, whereas PEI-HA nanoparticles primarily elicited IgG1-dominant antibody responses (<xref rid="ref28" ref-type="bibr">Dong et al., 2022</xref>). Another study reported an overall magnitude of the immune response induced by SARS-CoV-2 spike glycoprotein (CoVLP) vaccine candidate adjuvanted with CpG 1,018 or AS03 (<xref rid="ref121" ref-type="bibr">Ward et al., 2021</xref>).</p><p>Recent reports have highlighted the efficacy of TLR7 agonist-adjuvanted vaccines in inducing robust immune responses against SARS-CoV-2. Vaccination with the S1 subunit of the SARS-CoV-2 spike protein, adjuvanted with TLR7 agonist, has been shown to induce potent humoral and cellular immunity in mice. This approach resulted in a balanced Th1/Th2 immune response and effectively induced neutralizing antibodies against SARS-CoV-2 and all variants of concern (B.1.1.7/alpha, B.1.351/beta, P.1/gamma, B.1.617.2/delta, and B.1.1.529/omicron), suggesting a great potential of this adjuvant-protein conjugate vaccine candidate (<xref rid="ref132" ref-type="bibr">Zhang et al., 2022</xref>). Another study also reported that a subunit SARS-CoV-2 vaccine with clinically relevant adjuvants such as alum, AS03 (a squalene-based adjuvant supplemented with &#945;-tocopherol), AS37 (a TLR7 ligand emulsified in alum), CpG1018 (a TLR9 ligand emulsified in alum), O/W 1849101 (a squalene-based adjuvant) induced durable protection in mice. However, TLR-agonist-based adjuvants CpG1018 and AS37 induced Th1-skewed CD4+&#8201;T cell responses. In contrast, alum, O/W, and AS03 induced a balanced Th1/Th2 response (<xref rid="ref47" ref-type="bibr">Grigoryan et al., 2022</xref>). Further supporting the potential of TLR agonists as adjuvants, a multicenter, double-blind, randomized, placebo-controlled trial demonstrated that SCB-2019 (30&#8201;&#956;g, adjuvanted with 1&#183;50&#8201;mg CpG-1018 and 0&#183;75&#8201;mg alum) provided notable protection against the entire severity spectrum of COVID-19 caused by circulating delta, gamma, and mu variants of SARS-CoV-2 (<xref rid="ref17" ref-type="bibr">Bravo et al., 2022</xref>). These findings highlight the promising role of TLR agonists as potential adjuvants. The TLR agonists adjuvants currently under development for SARS-CoV-2 vaccines are listed in <xref rid="tab2" ref-type="table">Table 2</xref>.</p><table-wrap position="float" id="tab2" orientation="portrait"><label>Table 2</label><caption><p>TLR agonists as vaccine adjuvants in SARS-CoV-2 vaccines.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top" rowspan="1" colspan="1">Vaccine name</th><th align="left" valign="top" rowspan="1" colspan="1">Sponsor/company</th><th align="left" valign="top" rowspan="1" colspan="1">TLR agonist adjuvant</th><th align="left" valign="top" rowspan="1" colspan="1">Target TLR</th><th align="left" valign="top" rowspan="1" colspan="1">Clinical phase</th><th align="left" valign="top" rowspan="1" colspan="1">Disease target</th><th align="left" valign="top" rowspan="1" colspan="1">Effects on host immunity</th><th align="left" valign="top" rowspan="1" colspan="1">Clinical Trials. Gov identifier/reference</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">SCB-2019</td><td align="left" valign="top" rowspan="1" colspan="1">-</td><td align="left" valign="top" rowspan="1" colspan="1">CpG-1018</td><td align="left" valign="top" rowspan="1" colspan="1">TLR9</td><td align="left" valign="top" rowspan="1" colspan="1">Phase II/III</td><td align="left" valign="top" rowspan="1" colspan="1">COVID-19</td><td align="left" valign="top" rowspan="1" colspan="1">Provides notable protection against all circulating delta, gamma and mu variants of SARS-CoV-2</td><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="ref17" ref-type="bibr">Bravo et al. (2022)</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">SCB-2019 Recombinant SARS-CoV-2 Trimeric S-protein Subunit Vaccine</td><td align="left" valign="top" rowspan="1" colspan="1">Zhejiang Clover Biopharmaceuticals, Inc.</td><td align="left" valign="top" rowspan="1" colspan="1">CpG 1,018/Alum-adjuvanted</td><td align="left" valign="top" rowspan="1" colspan="1">TLR9</td><td align="left" valign="top" rowspan="1" colspan="1">Phase II</td><td align="left" valign="top" rowspan="1" colspan="1">COVID-19</td><td align="left" valign="top" rowspan="1" colspan="1">Results yet to be published</td><td align="left" valign="top" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04954131">NCT04954131</ext-link></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CoVac-1 (COVID-19 peptide vaccine)</td><td align="left" valign="top" rowspan="1" colspan="1">The University Hospital T&#252;bingen</td><td align="left" valign="top" rowspan="1" colspan="1">TLR 1/2 agonist XS15</td><td align="left" valign="top" rowspan="1" colspan="1">TLR 1/2</td><td align="left" valign="top" rowspan="1" colspan="1">Phase I</td><td align="left" valign="top" rowspan="1" colspan="1">COVID-19</td><td align="left" valign="top" rowspan="1" colspan="1">CoVac-1-induces IFN-&#947; T cell responses; induces broad, potent and variant of concern-independent T cell responses</td><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="ref50" ref-type="bibr">Heitmann et al. (2022)</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">SARS-CoV-2 subunit vaccine</td><td align="left" valign="top" rowspan="1" colspan="1">Georgia Institute of Technology, USA</td><td align="left" valign="top" rowspan="1" colspan="1">MPLA</td><td align="left" valign="top" rowspan="1" colspan="1">TLR4</td><td align="left" valign="top" rowspan="1" colspan="1">Phase I</td><td align="left" valign="top" rowspan="1" colspan="1">COVID-19</td><td align="left" valign="top" rowspan="1" colspan="1">In mice model, MPLA+PUUC NPs enhanced CD4+&#8201;CD44+ activated memory T cell responses against spike protein in the lungs while MPLA NPs increased anti-spike IgA in the bronchoalveolar fluid and IgG in the blood</td><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="ref9" ref-type="bibr">Atalis et al. (2022)</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">TLR7-NP adjuvanted SARS-CoV-2 vaccine</td><td align="left" valign="top" rowspan="1" colspan="1">Stanford University, USA</td><td align="left" valign="top" rowspan="1" colspan="1">Toll-like receptor 7 agonist nanoparticle (TLR7-NP)</td><td align="left" valign="top" rowspan="1" colspan="1">TLR7</td><td align="left" valign="top" rowspan="1" colspan="1">Phase I</td><td align="left" valign="top" rowspan="1" colspan="1">COVID-19</td><td align="left" valign="top" rowspan="1" colspan="1">Induces cross-reactive Abs for both dominant and subdominant epitopes and antigen-specific CD8+ T-cell responses in mice</td><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="ref130" ref-type="bibr">Yin et al. (2023)</xref>
</td></tr></tbody></table></table-wrap></sec><sec id="sec7"><title>TLR agonists as vaccine adjuvants in influenza virus vaccine</title><p>The development of more effective vaccines is required to combat influenza virus infection, and remains as a major goal of modern medical research. The use of TLR agonists in enhancing the influenza virus vaccine is under development. A reduced influenza-associated secondary pneumococcal infections has been reported in mice with co-administration of an inhaled TLR2 agonist with an inactivated vaccine (<xref rid="ref53" ref-type="bibr">Hussell and Goenka, 2016</xref>), also highlight the effectiveness of TLR agonist use in influenza vaccine. Lopez et al. reported an enhanced vaccine efficacy with enhanced antibody response in case of Encevac TC4 vaccine administration along with TLR9 agonist, CpG oligodeoxynucleotides (<xref rid="ref80" ref-type="bibr">Lopez et al., 2006</xref>). Flagellin, the structural component of bacterial flagella, is known as the TLR5 agonist that can cause the induction of cytokines and chemokines (<xref rid="ref41" ref-type="bibr">Gewirtz et al., 2001</xref>; <xref rid="ref81" ref-type="bibr">Lu and Sun, 2012</xref>). TLR5 also shows the potential to activate the immune cells and can initiate innate and adaptive immune response (<xref rid="ref49" ref-type="bibr">Hajam et al., 2017</xref>). The use of bacterial flagellin as TLR5 agonist in viral vaccine appears promising (<xref rid="ref49" ref-type="bibr">Hajam et al., 2017</xref>). Notably, flagellin has been extensively investigated as a mucosal adjuvant in epitope-based influenza vaccines, and appeared promising (<xref rid="ref14" ref-type="bibr">Ben-Yedidia and Arnon, 2007</xref>; <xref rid="ref107" ref-type="bibr">Song et al., 2008</xref>; <xref rid="ref2" ref-type="bibr">Adar et al., 2009</xref>; <xref rid="ref78" ref-type="bibr">Liu et al., 2011</xref>; <xref rid="ref113" ref-type="bibr">Taylor et al., 2011</xref>).</p><p>In murine model, Goff et al. reported that recombinant hemagglutinin (HA) from the A/Puerto Rico/8/1934 strain (rPR/8 HA) in combination with TLR4 (1Z105, a substituted pyrimido[5,4-b]indole specific for the TLR4-MD2 complex) and TLR7 ligands (1&#8201;V270, a phospholipid-conjugated agonist) can induce rapid and sustained humoral immunity that is protective against lethal challenge with a homologous virus (<xref rid="ref43" ref-type="bibr">Goff et al., 2015</xref>). Another study also showed that a dual combination of TLR4 and TLR7 ligands in recombinant influenza virus HA vaccine can induce a broader immune response (<xref rid="ref104" ref-type="bibr">Sato-Kaneko et al., 2020</xref>). A previous study reported an enhanced efficacy of split-virus vaccines (SVVs)-mediated protection against influenza in older adults when combined with TLR4 agonist glucopyranosyl lipid adjuvant&#8211;stable emulsion (GLA-SE; <xref rid="ref13" ref-type="bibr">Behzad et al., 2012</xref>). In a phase 2 clinical trial, an enhanced efficacy of H5N1 plant-made virus-like particle vaccine was observed when co-administered with GLA-SE (<xref rid="ref98" ref-type="bibr">Pillet et al., 2018</xref>). A sustained polyfunctional and cross-reactive HA-specific CD4+ T cell response was observed in all vaccinated groups (<xref rid="ref98" ref-type="bibr">Pillet et al., 2018</xref>).</p><p>Among the imidazoquinoline compounds, 1-benzyl-2-butyl-1H-imidazo[4,5-c]quinolin-4-amine (BBIQ) is a potential TLR7 agonist, and it was shown that recombinant influenza HA protein vaccine administered with BBIQ significantly enhanced anti-influenza IgG1 and IgG2c response in mice (<xref rid="ref63" ref-type="bibr">Kaushik et al., 2020</xref>), suggesting BBIQ as a promising influenza vaccine adjuvant for further study. In another study, a licensed quadrivalent inactivated influenza vaccine (QIV) administered with RIG-I (SDI-nanogel) and TLR7/8 agonist (Imidazoquinoline) enhanced antibody and T cell responses, correlating with the protection against lethal influenza virus infection (<xref rid="ref58" ref-type="bibr">Jangra et al., 2022</xref>). Clemens et al. reported that stem region of the HA adjuvanted with R848 (TLR7/8 agonist) could impact multiple cell types such as influenza-specific T follicular helper cells as well as Tregs that have the potential to contribute to the HA-stem response (<xref rid="ref23" ref-type="bibr">Clemens et al., 2022</xref>). Overall, the use of TLR agonists in influenza vaccine might help in the development of more effective influenza vaccine in the near future.</p></sec><sec id="sec8"><title>TLR agonists as vaccine adjuvants in vaccines against flavivirus infections, including West Nile virus, dengue virus, and chikungunya virus</title><p>TLR agonist adjuvants represent a promising tool toward enhancing the protective capacity of flavivirus vaccines and broadening of antiviral antibody responses with reduced dose and dosage (<xref rid="ref117" ref-type="bibr">Van Hoeven et al., 2018</xref>). Currently there is no approved human vaccine for WNV. In a recent study, it has been shown that WNV recombinant E-protein vaccine (WN-80E) adjuvanted with TLR4 agonist SLA or the saponin adjuvant, QS21 was capable of inducing long-lasting immune responses in preclinical models with sterilizing protection in WNV challenge, reducing viral titers following WNV challenge to below detection levels in Syrian hamsters (<italic toggle="yes">Mesocricetus auratus</italic>; <xref rid="ref117" ref-type="bibr">Van Hoeven et al., 2018</xref>). Flagellin has also been investigated as a mucosal adjuvant to be used in WNV recombinant protein vaccine with the induction of protective immune response (<xref rid="ref89" ref-type="bibr">McDonald et al., 2007</xref>).</p><p>A DENV vaccine that is equally effective against all four serotypes is urgently needed. Toward the development of a panserotype dengue vaccine, the suitability of using TLR agonist as an adjuvant could be helpful (<xref rid="ref70" ref-type="bibr">Kayesh et al., 2021b</xref>). A recent study investigated the immunogenicity and protective capacity of recombinant DENV NS1 administered with CDNs. It was observed that NS1-CDN immunizations could induce serotype-specific and cross-reactive antibody and T-cell responses in mice model. Further, NS1-CDN vaccinations showed efficacy in homotypic and heterotypic protection from DENV2-induced morbidity and mortality (<xref rid="ref34" ref-type="bibr">Espinosa et al., 2019</xref>). It has been shown that dengue subunit vaccine consisted of recombinant DENV2 envelope domain III combined with TLR agonists induced strong immunological signatures involving immune cell trafficking, IFNs, and proinflammatory and T-cell responses, however, unexpectedly only partial protection was obtained against viral challenge (<xref rid="ref16" ref-type="bibr">Bidet et al., 2019</xref>).</p><p>Until recently, there was no clinically approved CHIKV vaccine for immunization, however, on 9th November 2023, the U.S. Food and Drug Administration approved the first chikungunya vaccine, Ixchiq/VLA1553 (developed by Valneva Austria GmbH) for individuals 18&#8201;years of age and older who are at increased risk of exposure to CHIKV (<xref rid="ref115" ref-type="bibr">U.S. Food and Drug Administration, 2023</xref>). In a multicenter, randomized, placebo-controlled phase 3 clinical study, CHIKV vaccine VLA1553 was found generally safe and equally well tolerated in younger and older adults that induced seroprotective chikungunya virus neutralizing antibody levels in 263 (98&#183;9%) of 266 participants (<xref rid="ref105" ref-type="bibr">Schneider et al., 2023</xref>). A recent study reported an enhanced efficacy of inactivated CHIKV-MPLA combination, which could induce higher neutralizing antibodies compared to unadjuvanted CHIKV vaccine (<xref rid="ref46" ref-type="bibr">Gosavi and Patil, 2022</xref>). Although further studies are warranted, however, TLR4 agonist appears as a promising adjuvant candidate to be used for enhancing the efficacy of CHIKV vaccine (<xref rid="ref46" ref-type="bibr">Gosavi and Patil, 2022</xref>).</p></sec><sec sec-type="discussion" id="sec9"><title>Discussion</title><p>Appropriate selection of specific pattern recognition receptor ligands (adjuvants) is critical for formulating the next generation vaccines, which will aim to induce an efficient adaptive immune response with minimal adverse reactions. Both the existing vaccines and new vaccine development could benefit from the use of TLR agonists as vaccine adjuvants, especially for viral vaccines targeting particular pathogens (<xref rid="ref69" ref-type="bibr">Kayesh et al., 2021a</xref>). However, it is important to emphasize the need for comparative studies before selecting a TLR agonist as an adjuvant, and there is a currently a lack of research comparing the nature of immune responses induced by different candidate adjuvants.</p></sec><sec id="sec10"><title>Limitation and future perspectives</title><p>Although TLR agonists appear as potent immune activators for immunomodulation, however, TLR activation-induced signaling may act as a double-edged sword, which may enhance immune-mediated pathologies instead of protection (<xref rid="ref103" ref-type="bibr">Salaun et al., 2007</xref>; <xref rid="ref52" ref-type="bibr">Huang et al., 2008</xref>; <xref rid="ref131" ref-type="bibr">Yokota et al., 2010</xref>). Therefore, a clear understanding of TLR interactions with particular virus is critical for judicious use of TLR agonist in the vaccine. More preclinical studies are essential to perform for investigating the challenges of TLR use both in vaccines as well as in therapy. In addition, as combined use of TLR agonists is assumed to enhance the immune response, therefore, more future studies are warranted for investigating the combinatorial use of multiple TLR agonist and their effects on vaccine use (<xref rid="ref4" ref-type="bibr">Albin et al., 2019</xref>). Also, the use of TLR agonist as vaccine adjuvants can be extended for investigation in other viral vaccines.</p></sec><sec sec-type="conclusions" id="sec11"><title>Conclusion</title><p>The use of TLR agonists as vaccine adjuvant has revolutionized the modern vaccine science due to its potential in improving vaccine effectiveness. In addition, TLR agonist has opened up a new research window for enhancing efficacy of the existing vaccines as well as for developing the new vaccines. Many TLR agonist candidates are under investigation, and by proper tailoring of TLR agonists in vaccine formulation, the vaccine effectiveness can be improved that should help in protecting chronic and emerging viral diseases.</p></sec><sec sec-type="author-contributions" id="sec12"><title>Author contributions</title><p>MEHK, MK, and KT-K: conceptualization and writing&#8212;review and editing. MEHK and KT-K: writing&#8212;original draft preparation. All authors contributed to the article and approved the submitted version.</p></sec></body><back><sec sec-type="COI-statement" id="sec14"><title>Conflict of interest</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec><sec sec-type="disclaimer" id="sec100"><title>Publisher&#8217;s note</title><p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec><ref-list><title>References</title><ref id="ref1"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abhyankar</surname><given-names>M. M.</given-names></name><name name-style="western"><surname>Mann</surname><given-names>B. J.</given-names></name><name name-style="western"><surname>Sturek</surname><given-names>J. M.</given-names></name><name name-style="western"><surname>Brovero</surname><given-names>S.</given-names></name><name name-style="western"><surname>Moreau</surname><given-names>G. B.</given-names></name><name name-style="western"><surname>Sengar</surname><given-names>A.</given-names></name><etal/></person-group>. (<year>2021</year>). <article-title>Development of COVID-19 vaccine using a dual toll-like receptor ligand liposome adjuvant</article-title>. <source>NPJ Vaccines</source><volume>6</volume>:<fpage>137</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41541-021-00399-0</pub-id>, PMID: <pub-id pub-id-type="pmid">34795290</pub-id><pub-id pub-id-type="pmcid">PMC8602664</pub-id></mixed-citation></ref><ref id="ref2"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Adar</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Singer</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Levi</surname><given-names>R.</given-names></name><name name-style="western"><surname>Tzehoval</surname><given-names>E.</given-names></name><name name-style="western"><surname>Perk</surname><given-names>S.</given-names></name><name name-style="western"><surname>Banet-Noach</surname><given-names>C.</given-names></name><etal/></person-group>. (<year>2009</year>). <article-title>A universal epitope-based influenza vaccine and its efficacy against H5N1</article-title>. <source>Vaccine</source><volume>27</volume>, <fpage>2099</fpage>&#8211;<lpage>2107</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.vaccine.2009.02.011</pub-id>, PMID: <pub-id pub-id-type="pmid">19356612</pub-id></mixed-citation></ref><ref id="ref3"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Agrawal</surname><given-names>S.</given-names></name><name name-style="western"><surname>Agrawal</surname><given-names>A.</given-names></name><name name-style="western"><surname>Doughty</surname><given-names>B.</given-names></name><name name-style="western"><surname>Gerwitz</surname><given-names>A.</given-names></name><name name-style="western"><surname>Blenis</surname><given-names>J.</given-names></name><name name-style="western"><surname>Van Dyke</surname><given-names>T.</given-names></name><etal/></person-group>. (<year>2003</year>). <article-title>Cutting edge: different toll-like receptor agonists instruct dendritic cells to induce distinct Th responses via differential modulation of extracellular signal-regulated kinase-mitogen-activated protein kinase and c-Fos</article-title>. <source>J. Immunol.</source><volume>171</volume>, <fpage>4984</fpage>&#8211;<lpage>4989</lpage>. doi: <pub-id pub-id-type="doi">10.4049/jimmunol.171.10.4984</pub-id><pub-id pub-id-type="pmid">14607893</pub-id></mixed-citation></ref><ref id="ref4"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Albin</surname><given-names>T. J.</given-names></name><name name-style="western"><surname>Tom</surname><given-names>J. K.</given-names></name><name name-style="western"><surname>Manna</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gilkes</surname><given-names>A. P.</given-names></name><name name-style="western"><surname>Stetkevich</surname><given-names>S. A.</given-names></name><name name-style="western"><surname>Katz</surname><given-names>B. B.</given-names></name><etal/></person-group>. (<year>2019</year>). <article-title>Linked toll-like receptor Triagonists stimulate distinct, combination-dependent innate immune responses</article-title>. <source>ACS Cent Sci</source><volume>5</volume>, <fpage>1137</fpage>&#8211;<lpage>1145</lpage>. doi: <pub-id pub-id-type="doi">10.1021/acscentsci.8b00823</pub-id>, PMID: <pub-id pub-id-type="pmid">31403067</pub-id><pub-id pub-id-type="pmcid">PMC6661867</pub-id></mixed-citation></ref><ref id="ref5"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Amin</surname><given-names>O. E.</given-names></name><name name-style="western"><surname>Colbeck</surname><given-names>E. J.</given-names></name><name name-style="western"><surname>Daffis</surname><given-names>S.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ramakrishnan</surname><given-names>D.</given-names></name><name name-style="western"><surname>Pattabiraman</surname><given-names>D.</given-names></name><etal/></person-group>. (<year>2021</year>). <article-title>Therapeutic potential of TLR8 agonist GS-9688 (Selgantolimod) in chronic hepatitis B: remodeling of antiviral and regulatory mediators</article-title>. <source>Hepatology</source><volume>74</volume>, <fpage>55</fpage>&#8211;<lpage>71</lpage>. doi: <pub-id pub-id-type="doi">10.1002/hep.31695</pub-id>, PMID: <pub-id pub-id-type="pmid">33368377</pub-id><pub-id pub-id-type="pmcid">PMC8436741</pub-id></mixed-citation></ref><ref id="ref6"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Anguille</surname><given-names>S.</given-names></name><name name-style="western"><surname>Van Acker</surname><given-names>H. H.</given-names></name><name name-style="western"><surname>Van Den Bergh</surname><given-names>J.</given-names></name><name name-style="western"><surname>Willemen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Goossens</surname><given-names>H.</given-names></name><name name-style="western"><surname>Van Tendeloo</surname><given-names>V. F.</given-names></name><etal/></person-group>. (<year>2015</year>). <article-title>Interleukin-15 dendritic cells harness NK cell cytotoxic effector function in a contact- and IL-15-dependent manner</article-title>. <source>PloS One</source><volume>10</volume>:<fpage>e0123340</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0123340</pub-id><pub-id pub-id-type="pmid">25951230</pub-id><pub-id pub-id-type="pmcid">PMC4423923</pub-id></mixed-citation></ref><ref id="ref7"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arunachalam</surname><given-names>P. S.</given-names></name><name name-style="western"><surname>Walls</surname><given-names>A. C.</given-names></name><name name-style="western"><surname>Golden</surname><given-names>N.</given-names></name><name name-style="western"><surname>Atyeo</surname><given-names>C.</given-names></name><name name-style="western"><surname>Fischinger</surname><given-names>S.</given-names></name><name name-style="western"><surname>Li</surname><given-names>C.</given-names></name><etal/></person-group>. (<year>2021</year>). <article-title>Adjuvanting a subunit COVID-19 vaccine to induce protective immunity</article-title>. <source>Nature</source><volume>594</volume>, <fpage>253</fpage>&#8211;<lpage>258</lpage>. doi: <pub-id pub-id-type="doi">10.1038/s41586-021-03530-2</pub-id><pub-id pub-id-type="pmid">33873199</pub-id></mixed-citation></ref><ref id="ref8"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Assad</surname><given-names>S.</given-names></name><name name-style="western"><surname>Francis</surname><given-names>A.</given-names></name></person-group> (<year>1999</year>). <article-title>Over a decade of experience with a yeast recombinant hepatitis B vaccine</article-title>. <source>Vaccine</source><volume>18</volume>, <fpage>57</fpage>&#8211;<lpage>67</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0264-410X(99)00179-6</pub-id>, PMID: <pub-id pub-id-type="pmid">10501235</pub-id></mixed-citation></ref><ref id="ref9"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Atalis</surname><given-names>A.</given-names></name><name name-style="western"><surname>Keenum</surname><given-names>M. C.</given-names></name><name name-style="western"><surname>Pandey</surname><given-names>B.</given-names></name><name name-style="western"><surname>Beach</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pradhan</surname><given-names>P.</given-names></name><name name-style="western"><surname>Vantucci</surname><given-names>C.</given-names></name><etal/></person-group>. (<year>2022</year>). <article-title>Nanoparticle-delivered TLR4 and RIG-I agonists enhance immune response to SARS-CoV-2 subunit vaccine</article-title>. <source>J. Control. Release</source><volume>347</volume>, <fpage>476</fpage>&#8211;<lpage>488</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jconrel.2022.05.023</pub-id>, PMID: <pub-id pub-id-type="pmid">35577151</pub-id><pub-id pub-id-type="pmcid">PMC9121740</pub-id></mixed-citation></ref><ref id="ref10"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Awate</surname><given-names>S.</given-names></name><name name-style="western"><surname>Babiuk</surname><given-names>L. A.</given-names></name><name name-style="western"><surname>Mutwiri</surname><given-names>G.</given-names></name></person-group> (<year>2013</year>). <article-title>Mechanisms of action of adjuvants</article-title>. <source>Front. Immunol.</source><volume>4</volume>:<fpage>114</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fimmu.2013.00114</pub-id><pub-id pub-id-type="pmid">23720661</pub-id><pub-id pub-id-type="pmcid">PMC3655441</pub-id></mixed-citation></ref><ref id="ref11"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baylor</surname><given-names>N. W.</given-names></name><name name-style="western"><surname>Egan</surname><given-names>W.</given-names></name><name name-style="western"><surname>Richman</surname><given-names>P.</given-names></name></person-group> (<year>2002</year>). <article-title>Aluminum salts in vaccines&#8212;US perspective</article-title>. <source>Vaccine</source><volume>20</volume>, <fpage>S18</fpage>&#8211;<lpage>S23</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0264-410X(02)00166-4</pub-id><pub-id pub-id-type="pmid">12184360</pub-id></mixed-citation></ref><ref id="ref12"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Behmard</surname><given-names>E.</given-names></name><name name-style="western"><surname>Abdulabbas</surname><given-names>H. T.</given-names></name><name name-style="western"><surname>Abdalkareem Jasim</surname><given-names>S.</given-names></name><name name-style="western"><surname>Najafipour</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ghasemian</surname><given-names>A.</given-names></name><name name-style="western"><surname>Farjadfar</surname><given-names>A.</given-names></name><etal/></person-group>. (<year>2022</year>). <article-title>Design of a novel multi-epitope vaccine candidate against hepatitis C virus using structural and nonstructural proteins: an immunoinformatics approach</article-title>. <source>PloS One</source><volume>17</volume>:<fpage>e0272582</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0272582</pub-id>, PMID: <pub-id pub-id-type="pmid">36040967</pub-id><pub-id pub-id-type="pmcid">PMC9426923</pub-id></mixed-citation></ref><ref id="ref13"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Behzad</surname><given-names>H.</given-names></name><name name-style="western"><surname>Huckriede</surname><given-names>A. L.</given-names></name><name name-style="western"><surname>Haynes</surname><given-names>L.</given-names></name><name name-style="western"><surname>Gentleman</surname><given-names>B.</given-names></name><name name-style="western"><surname>Coyle</surname><given-names>K.</given-names></name><name name-style="western"><surname>Wilschut</surname><given-names>J. C.</given-names></name><etal/></person-group>. (<year>2012</year>). <article-title>GLA-SE, a synthetic toll-like receptor 4 agonist, enhances T-cell responses to influenza vaccine in older adults</article-title>. <source>J Infect Dis</source><volume>205</volume>, <fpage>466</fpage>&#8211;<lpage>473</lpage>. doi: <pub-id pub-id-type="doi">10.1093/infdis/jir769</pub-id>, PMID: <pub-id pub-id-type="pmid">22147791</pub-id><pub-id pub-id-type="pmcid">PMC3256953</pub-id></mixed-citation></ref><ref id="ref14"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ben-Yedidia</surname><given-names>T.</given-names></name><name name-style="western"><surname>Arnon</surname><given-names>R.</given-names></name></person-group> (<year>2007</year>). <article-title>Epitope-based vaccine against influenza</article-title>. <source>Expert Rev. Vaccines</source><volume>6</volume>, <fpage>939</fpage>&#8211;<lpage>948</lpage>. doi: <pub-id pub-id-type="doi">10.1586/14760584.6.6.939</pub-id><pub-id pub-id-type="pmid">18034655</pub-id></mixed-citation></ref><ref id="ref15"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bezemer</surname><given-names>G. F. G.</given-names></name><name name-style="western"><surname>Garssen</surname><given-names>J.</given-names></name></person-group> (<year>2020</year>). <article-title>TLR9 and COVID-19: a multidisciplinary theory of a multifaceted therapeutic target</article-title>. <source>Front. Pharmacol.</source><volume>11</volume>:<fpage>601685</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fphar.2020.601685</pub-id><pub-id pub-id-type="pmid">33519463</pub-id><pub-id pub-id-type="pmcid">PMC7844586</pub-id></mixed-citation></ref><ref id="ref16"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bidet</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ho</surname><given-names>V.</given-names></name><name name-style="western"><surname>Chu</surname><given-names>C. W.</given-names></name><name name-style="western"><surname>Naim</surname><given-names>A. N. H.</given-names></name><name name-style="western"><surname>Thazin</surname><given-names>K.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>K. R.</given-names></name><etal/></person-group>. (<year>2019</year>). <article-title>Mimicking immune signatures of flavivirus infection with targeted adjuvants improves dengue subunit vaccine immunogenicity</article-title>. <source>NPJ Vaccines</source><volume>4</volume>:<fpage>27</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41541-019-0119-3</pub-id>, PMID: <pub-id pub-id-type="pmid">31285858</pub-id><pub-id pub-id-type="pmcid">PMC6592935</pub-id></mixed-citation></ref><ref id="ref17"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bravo</surname><given-names>L.</given-names></name><name name-style="western"><surname>Smolenov</surname><given-names>I.</given-names></name><name name-style="western"><surname>Han</surname><given-names>H. H.</given-names></name><name name-style="western"><surname>Li</surname><given-names>P.</given-names></name><name name-style="western"><surname>Hosain</surname><given-names>R.</given-names></name><name name-style="western"><surname>Rockhold</surname><given-names>F.</given-names></name><etal/></person-group>. (<year>2022</year>). <article-title>Efficacy of the adjuvanted subunit protein COVID-19 vaccine, SCB-2019: a phase 2 and 3 multicentre, double-blind, randomised, placebo-controlled trial</article-title>. <source>Lancet</source><volume>399</volume>, <fpage>461</fpage>&#8211;<lpage>472</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0140-6736(22)00055-1</pub-id>, PMID: <pub-id pub-id-type="pmid">35065705</pub-id><pub-id pub-id-type="pmcid">PMC8776284</pub-id></mixed-citation></ref><ref id="ref18"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brown</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Hajishengallis</surname><given-names>G. N.</given-names></name><name name-style="western"><surname>Martin</surname><given-names>M.</given-names></name></person-group> (<year>2011</year>). <article-title>TLR-signaling networks: an integration of adaptor molecules, kinases, and cross-talk</article-title>. <source>J. Dent. Res.</source><volume>90</volume>, <fpage>417</fpage>&#8211;<lpage>427</lpage>. doi: <pub-id pub-id-type="doi">10.1177/0022034510381264</pub-id>, PMID: <pub-id pub-id-type="pmid">20940366</pub-id><pub-id pub-id-type="pmcid">PMC3075579</pub-id></mixed-citation></ref><ref id="ref19"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Catherine</surname><given-names>F. X.</given-names></name><name name-style="western"><surname>Piroth</surname><given-names>L.</given-names></name></person-group> (<year>2017</year>). <article-title>Hepatitis B virus vaccination in HIV-infected people: a review</article-title>. <source>Hum. Vaccin. Immunother.</source><volume>13</volume>, <fpage>1</fpage>&#8211;<lpage>10</lpage>. doi: <pub-id pub-id-type="doi">10.1080/21645515.2016.1277844</pub-id>, PMID: <pub-id pub-id-type="pmid">28267387</pub-id><pub-id pub-id-type="pmcid">PMC5489285</pub-id></mixed-citation></ref><ref id="ref20"><mixed-citation publication-type="journal"><person-group person-group-type="author"><collab id="coll1">Centers for Disease Control and Prevention</collab></person-group> (<year>2010</year>). <article-title>FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the advisory committee on immunization practices (ACIP)</article-title>. <source>MMWR Morb. Mortal. Wkly Rep.</source><volume>59</volume>, <fpage>626</fpage>&#8211;<lpage>629</lpage>. PMID: <pub-id pub-id-type="pmid">20508593</pub-id></mixed-citation></ref><ref id="ref21"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chinchilla-Lopez</surname><given-names>P.</given-names></name><name name-style="western"><surname>Qi</surname><given-names>X.</given-names></name><name name-style="western"><surname>Yoshida</surname><given-names>E. M.</given-names></name><name name-style="western"><surname>Mendez-Sanchez</surname><given-names>N.</given-names></name></person-group> (<year>2017</year>). <article-title>The direct-acting antivirals for hepatitis C virus and the risk for hepatocellular carcinoma</article-title>. <source>Ann. Hepatol.</source><volume>16</volume>, <fpage>328</fpage>&#8211;<lpage>330</lpage>. doi: <pub-id pub-id-type="doi">10.5604/01.3001.0009.8585</pub-id><pub-id pub-id-type="pmid">28425400</pub-id></mixed-citation></ref><ref id="ref22"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chua</surname><given-names>B. Y.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>D.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Earnest-Silveira</surname><given-names>L.</given-names></name><name name-style="western"><surname>Sekiya</surname><given-names>T.</given-names></name><name name-style="western"><surname>Chin</surname><given-names>R.</given-names></name><etal/></person-group>. (<year>2012</year>). <article-title>Hepatitis C VLPs delivered to dendritic cells by a TLR2 targeting lipopeptide results in enhanced antibody and cell-mediated responses</article-title>. <source>PloS One</source><volume>7</volume>:<fpage>e47492</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0047492</pub-id>, PMID: <pub-id pub-id-type="pmid">23091628</pub-id><pub-id pub-id-type="pmcid">PMC3472981</pub-id></mixed-citation></ref><ref id="ref23"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Clemens</surname><given-names>E. A.</given-names></name><name name-style="western"><surname>Holbrook</surname><given-names>B. C.</given-names></name><name name-style="western"><surname>Mcneilly</surname><given-names>B.</given-names></name><name name-style="western"><surname>Kanekiyo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Graham</surname><given-names>B. S.</given-names></name><name name-style="western"><surname>Alexander-Miller</surname><given-names>M. A.</given-names></name></person-group> (<year>2022</year>). <article-title>TLR agonists induce sustained IgG to hemagglutinin stem and modulate T cells following newborn vaccination</article-title>. <source>NPJ Vaccines</source><volume>7</volume>:<fpage>102</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41541-022-00523-8</pub-id>, PMID: <pub-id pub-id-type="pmid">36038596</pub-id><pub-id pub-id-type="pmcid">PMC9424286</pub-id></mixed-citation></ref><ref id="ref24"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Daffis</surname><given-names>S.</given-names></name><name name-style="western"><surname>Balsitis</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chamberlain</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>J.</given-names></name><name name-style="western"><surname>Santos</surname><given-names>R.</given-names></name><name name-style="western"><surname>Rowe</surname><given-names>W.</given-names></name><etal/></person-group>. (<year>2021</year>). <article-title>Toll-like receptor 8 agonist GS-9688 induces sustained efficacy in the woodchuck model of chronic hepatitis B</article-title>. <source>Hepatology</source><volume>73</volume>, <fpage>53</fpage>&#8211;<lpage>67</lpage>. doi: <pub-id pub-id-type="doi">10.1002/hep.31255</pub-id>, PMID: <pub-id pub-id-type="pmid">32246499</pub-id><pub-id pub-id-type="pmcid">PMC7898792</pub-id></mixed-citation></ref><ref id="ref25"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Vries-Sluijs</surname><given-names>T.</given-names></name><name name-style="western"><surname>Andrinopoulou</surname><given-names>E. R.</given-names></name><name name-style="western"><surname>De Man</surname><given-names>R. A.</given-names></name><name name-style="western"><surname>Van Der Ende</surname><given-names>M. E.</given-names></name></person-group> (<year>2020</year>). <article-title>Fendrix(R) compared to Engerix(R) in HIV-infected patients nonresponding to initial- and re-vaccination schedule</article-title>. <source>Neth. J. Med.</source><volume>78</volume>, <fpage>376</fpage>&#8211;<lpage>380</lpage>. PMID: <pub-id pub-id-type="pmid">33380535</pub-id></mixed-citation></ref><ref id="ref26"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Didierlaurent</surname><given-names>A. M.</given-names></name><name name-style="western"><surname>Morel</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lockman</surname><given-names>L.</given-names></name><name name-style="western"><surname>Giannini</surname><given-names>S. L.</given-names></name><name name-style="western"><surname>Bisteau</surname><given-names>M.</given-names></name><name name-style="western"><surname>Carlsen</surname><given-names>H.</given-names></name><etal/></person-group>. (<year>2009</year>). <article-title>AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity</article-title>. <source>J. Immunol.</source><volume>183</volume>, <fpage>6186</fpage>&#8211;<lpage>6197</lpage>. doi: <pub-id pub-id-type="doi">10.4049/jimmunol.0901474</pub-id>, PMID: <pub-id pub-id-type="pmid">19864596</pub-id></mixed-citation></ref><ref id="ref27"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dominguez-Molina</surname><given-names>B.</given-names></name><name name-style="western"><surname>Machmach</surname><given-names>K.</given-names></name><name name-style="western"><surname>Perales</surname><given-names>C.</given-names></name><name name-style="western"><surname>Tarancon-Diez</surname><given-names>L.</given-names></name><name name-style="western"><surname>Gallego</surname><given-names>I.</given-names></name><name name-style="western"><surname>Sheldon</surname><given-names>J. L.</given-names></name><etal/></person-group>. (<year>2018</year>). <article-title>Toll-like receptor 7 (TLR-7) and TLR-9 agonists improve hepatitis C virus replication and infectivity inhibition by Plasmacytoid dendritic cells</article-title>. <source>J. Virol.</source><volume>92</volume>:<fpage>18</fpage>. doi: <pub-id pub-id-type="doi">10.1128/JVI.01219-18</pub-id>, PMID: <pub-id pub-id-type="pmid">30232187</pub-id><pub-id pub-id-type="pmcid">PMC6232477</pub-id></mixed-citation></ref><ref id="ref28"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dong</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>L.</given-names></name><etal/></person-group>. (<year>2022</year>). <article-title>Polycationic HA/CpG nanoparticles induce cross-protective influenza immunity in mice</article-title>. <source>ACS Appl. Mater. Interfaces</source><volume>14</volume>, <fpage>6331</fpage>&#8211;<lpage>6342</lpage>. doi: <pub-id pub-id-type="doi">10.1021/acsami.1c19192</pub-id>, PMID: <pub-id pub-id-type="pmid">35084819</pub-id><pub-id pub-id-type="pmcid">PMC8832387</pub-id></mixed-citation></ref><ref id="ref29"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dowling</surname><given-names>D. J.</given-names></name></person-group> (<year>2018</year>). <article-title>Recent advances in the discovery and delivery of TLR7/8 agonists as vaccine adjuvants</article-title>. <source>Immunohorizons</source><volume>2</volume>, <fpage>185</fpage>&#8211;<lpage>197</lpage>. doi: <pub-id pub-id-type="doi">10.4049/immunohorizons.1700063</pub-id>, PMID: <pub-id pub-id-type="pmid">31022686</pub-id></mixed-citation></ref><ref id="ref30"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Duan</surname><given-names>T.</given-names></name><name name-style="western"><surname>Du</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xing</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H. Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>R. F.</given-names></name></person-group> (<year>2022</year>). <article-title>Toll-like receptor signaling and its role in cell-mediated immunity</article-title>. <source>Front. Immunol.</source><volume>13</volume>:<fpage>812774</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fimmu.2022.812774</pub-id>, PMID: <pub-id pub-id-type="pmid">35309296</pub-id><pub-id pub-id-type="pmcid">PMC8927970</pub-id></mixed-citation></ref><ref id="ref31"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dubensky</surname><given-names>T. W.</given-names></name><name name-style="western"><surname>Kanne</surname><given-names>D. B.</given-names></name><name name-style="western"><surname>Leong</surname><given-names>M. L.</given-names></name></person-group> (<year>2013</year>). <article-title>Rationale, progress and development of vaccines utilizing STING-activating cyclic dinucleotide adjuvants</article-title>. <source>Ther Adv Vaccines</source><volume>1</volume>, <fpage>131</fpage>&#8211;<lpage>143</lpage>. doi: <pub-id pub-id-type="doi">10.1177/2051013613501988</pub-id>, PMID: <pub-id pub-id-type="pmid">24757520</pub-id><pub-id pub-id-type="pmcid">PMC3991150</pub-id></mixed-citation></ref><ref id="ref32"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Edwards</surname><given-names>D. K.</given-names></name><name name-style="western"><surname>Jasny</surname><given-names>E.</given-names></name><name name-style="western"><surname>Yoon</surname><given-names>H.</given-names></name><name name-style="western"><surname>Horscroft</surname><given-names>N.</given-names></name><name name-style="western"><surname>Schanen</surname><given-names>B.</given-names></name><name name-style="western"><surname>Geter</surname><given-names>T.</given-names></name><etal/></person-group>. (<year>2017</year>). <article-title>Adjuvant effects of a sequence-engineered mRNA vaccine: translational profiling demonstrates similar human and murine innate response</article-title>. <source>J. Transl. Med.</source><volume>15</volume>:<fpage>1</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s12967-016-1111-6</pub-id>, PMID: <pub-id pub-id-type="pmid">28049494</pub-id><pub-id pub-id-type="pmcid">PMC5210268</pub-id></mixed-citation></ref><ref id="ref33"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eng</surname><given-names>N. F.</given-names></name><name name-style="western"><surname>Bhardwaj</surname><given-names>N.</given-names></name><name name-style="western"><surname>Mulligan</surname><given-names>R.</given-names></name><name name-style="western"><surname>Diaz-Mitoma</surname><given-names>F.</given-names></name></person-group> (<year>2013</year>). <article-title>The potential of 1018 ISS adjuvant in hepatitis B vaccines: HEPLISAV review</article-title>. <source>Hum. Vaccin. Immunother.</source><volume>9</volume>, <fpage>1661</fpage>&#8211;<lpage>1672</lpage>. doi: <pub-id pub-id-type="doi">10.4161/hv.24715</pub-id>, PMID: <pub-id pub-id-type="pmid">23732907</pub-id><pub-id pub-id-type="pmcid">PMC3906263</pub-id></mixed-citation></ref><ref id="ref34"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Espinosa</surname><given-names>D. A.</given-names></name><name name-style="western"><surname>Beatty</surname><given-names>P. R.</given-names></name><name name-style="western"><surname>Reiner</surname><given-names>G. L.</given-names></name><name name-style="western"><surname>Sivick</surname><given-names>K. E.</given-names></name><name name-style="western"><surname>Hix Glickman</surname><given-names>L.</given-names></name><name name-style="western"><surname>Dubensky</surname><given-names>T. W.</given-names></name><etal/></person-group>. (<year>2019</year>). <article-title>Cyclic dinucleotide-Adjuvanted dengue virus nonstructural protein 1 induces protective antibody and T cell responses</article-title>. <source>J. Immunol.</source><volume>202</volume>, <fpage>1153</fpage>&#8211;<lpage>1162</lpage>. doi: <pub-id pub-id-type="doi">10.4049/jimmunol.1801323</pub-id>, PMID: <pub-id pub-id-type="pmid">30642979</pub-id><pub-id pub-id-type="pmcid">PMC6363872</pub-id></mixed-citation></ref><ref id="ref35"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ezzikouri</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kayesh</surname><given-names>M. E. H.</given-names></name><name name-style="western"><surname>Benjelloun</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kohara</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tsukiyama-Kohara</surname><given-names>K.</given-names></name></person-group> (<year>2020</year>). <article-title>Targeting host innate and adaptive immunity to achieve the functional cure of chronic hepatitis B</article-title>. <source>Vaccines</source><volume>8</volume>:<fpage>216</fpage>. doi: <pub-id pub-id-type="doi">10.3390/vaccines8020216</pub-id><pub-id pub-id-type="pmid">32403281</pub-id><pub-id pub-id-type="pmcid">PMC7349973</pub-id></mixed-citation></ref><ref id="ref36"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fabrizi</surname><given-names>F.</given-names></name><name name-style="western"><surname>Cerutti</surname><given-names>R.</given-names></name><name name-style="western"><surname>Garcia-Agudo</surname><given-names>R.</given-names></name><name name-style="western"><surname>Bellincioni</surname><given-names>C.</given-names></name><name name-style="western"><surname>Porata</surname><given-names>G.</given-names></name><name name-style="western"><surname>Frontini</surname><given-names>G.</given-names></name><etal/></person-group>. (<year>2020</year>). <article-title>Adjuvanted recombinant HBV vaccine (HBV-AS04) is effective over extended follow-up in dialysis population. An open-label non randomized trial</article-title>. <source>Clin. Res. Hepatol. Gastroenterol.</source><volume>44</volume>, <fpage>905</fpage>&#8211;<lpage>912</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.clinre.2020.01.010</pub-id><pub-id pub-id-type="pmid">32144074</pub-id></mixed-citation></ref><ref id="ref37"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fabrizi</surname><given-names>F.</given-names></name><name name-style="western"><surname>Tarantino</surname><given-names>A.</given-names></name><name name-style="western"><surname>Castelnovo</surname><given-names>C.</given-names></name><name name-style="western"><surname>Martin</surname><given-names>P.</given-names></name><name name-style="western"><surname>Messa</surname><given-names>P.</given-names></name></person-group> (<year>2015</year>). <article-title>Recombinant hepatitis B vaccine Adjuvanted with AS04 in Dialysis patients: a prospective cohort study</article-title>. <source>Kidney Blood Press. Res.</source><volume>40</volume>, <fpage>584</fpage>&#8211;<lpage>592</lpage>. doi: <pub-id pub-id-type="doi">10.1159/000368534</pub-id>, PMID: <pub-id pub-id-type="pmid">26566033</pub-id></mixed-citation></ref><ref id="ref38"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fore</surname><given-names>F.</given-names></name><name name-style="western"><surname>Indriputri</surname><given-names>C.</given-names></name><name name-style="western"><surname>Mamutse</surname><given-names>J.</given-names></name><name name-style="western"><surname>Nugraha</surname><given-names>J.</given-names></name></person-group> (<year>2020</year>). <article-title>TLR10 and its unique anti-inflammatory properties and potential use as a target in therapeutics</article-title>. <source>Immune Netw</source><volume>20</volume>:<fpage>e21</fpage>. doi: <pub-id pub-id-type="doi">10.4110/in.2020.20.e21</pub-id>, PMID: <pub-id pub-id-type="pmid">32655969</pub-id><pub-id pub-id-type="pmcid">PMC7327153</pub-id></mixed-citation></ref><ref id="ref39"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fritz</surname><given-names>J. H.</given-names></name><name name-style="western"><surname>Le Bourhis</surname><given-names>L.</given-names></name><name name-style="western"><surname>Sellge</surname><given-names>G.</given-names></name><name name-style="western"><surname>Magalhaes</surname><given-names>J. G.</given-names></name><name name-style="western"><surname>Fsihi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kufer</surname><given-names>T. A.</given-names></name><etal/></person-group>. (<year>2007</year>). <article-title>Nod1-mediated innate immune recognition of peptidoglycan contributes to the onset of adaptive immunity</article-title>. <source>Immunity</source><volume>26</volume>, <fpage>445</fpage>&#8211;<lpage>459</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.immuni.2007.03.009</pub-id>, PMID: <pub-id pub-id-type="pmid">17433730</pub-id></mixed-citation></ref><ref id="ref40"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garcon</surname><given-names>N.</given-names></name><name name-style="western"><surname>Chomez</surname><given-names>P.</given-names></name><name name-style="western"><surname>Van Mechelen</surname><given-names>M.</given-names></name></person-group> (<year>2007</year>). <article-title>GlaxoSmithKline adjuvant systems in vaccines: concepts, achievements and perspectives</article-title>. <source>Expert Rev. Vaccines</source><volume>6</volume>, <fpage>723</fpage>&#8211;<lpage>739</lpage>. doi: <pub-id pub-id-type="doi">10.1586/14760584.6.5.723</pub-id><pub-id pub-id-type="pmid">17931153</pub-id></mixed-citation></ref><ref id="ref41"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gewirtz</surname><given-names>A. T.</given-names></name><name name-style="western"><surname>Navas</surname><given-names>T. A.</given-names></name><name name-style="western"><surname>Lyons</surname><given-names>S.</given-names></name><name name-style="western"><surname>Godowski</surname><given-names>P. J.</given-names></name><name name-style="western"><surname>Madara</surname><given-names>J. L.</given-names></name></person-group> (<year>2001</year>). <article-title>Cutting edge: bacterial flagellin activates basolaterally expressed TLR5 to induce epithelial proinflammatory gene expression</article-title>. <source>J. Immunol.</source><volume>167</volume>, <fpage>1882</fpage>&#8211;<lpage>1885</lpage>. doi: <pub-id pub-id-type="doi">10.4049/jimmunol.167.4.1882</pub-id>, PMID: <pub-id pub-id-type="pmid">11489966</pub-id></mixed-citation></ref><ref id="ref42"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Girndt</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pluer</surname><given-names>M.</given-names></name><name name-style="western"><surname>Dellanna</surname><given-names>F.</given-names></name><name name-style="western"><surname>Michelsen</surname><given-names>A. K.</given-names></name><name name-style="western"><surname>Beige</surname><given-names>J.</given-names></name><name name-style="western"><surname>Toussaint</surname><given-names>K.</given-names></name><etal/></person-group>. (<year>2022</year>). <article-title>Immunogenicity and safety of a booster dose of the hepatitis B vaccine HepB-CpG (HEPLISAV-B(R)) compared with HepB-Eng (Engerix-B(R)) and HepB-AS04 (Fendrix(R)) in adults receiving hemodialysis who previously received hepatitis B vaccination and are not seroprotected: results of a randomized, multicenter phase 3 study</article-title>. <source>Hum. Vaccin. Immunother.</source><volume>18</volume>:<fpage>2136912</fpage>. doi: <pub-id pub-id-type="doi">10.1080/21645515.2022.2136912</pub-id><pub-id pub-id-type="pmid">36269938</pub-id><pub-id pub-id-type="pmcid">PMC9746491</pub-id></mixed-citation></ref><ref id="ref43"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goff</surname><given-names>P. H.</given-names></name><name name-style="western"><surname>Hayashi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Martinez-Gil</surname><given-names>L.</given-names></name><name name-style="western"><surname>Corr</surname><given-names>M.</given-names></name><name name-style="western"><surname>Crain</surname><given-names>B.</given-names></name><name name-style="western"><surname>Yao</surname><given-names>S.</given-names></name><etal/></person-group>. (<year>2015</year>). <article-title>Synthetic toll-like receptor 4 (TLR4) and TLR7 ligands as influenza virus vaccine adjuvants induce rapid, sustained, and broadly protective responses</article-title>. <source>J. Virol.</source><volume>89</volume>, <fpage>3221</fpage>&#8211;<lpage>3235</lpage>. doi: <pub-id pub-id-type="doi">10.1128/JVI.03337-14</pub-id>, PMID: <pub-id pub-id-type="pmid">25568203</pub-id><pub-id pub-id-type="pmcid">PMC4337541</pub-id></mixed-citation></ref><ref id="ref44"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gogoi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Mansouri</surname><given-names>S.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>L.</given-names></name></person-group> (<year>2020</year>). <article-title>The age of cyclic dinucleotide vaccine adjuvants</article-title>. <source>Vaccines</source><volume>8</volume>:<fpage>453</fpage>. doi: <pub-id pub-id-type="doi">10.3390/vaccines8030453</pub-id><pub-id pub-id-type="pmid">32823563</pub-id><pub-id pub-id-type="pmcid">PMC7563944</pub-id></mixed-citation></ref><ref id="ref45"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gorden</surname><given-names>K. B.</given-names></name><name name-style="western"><surname>Gorski</surname><given-names>K. S.</given-names></name><name name-style="western"><surname>Gibson</surname><given-names>S. J.</given-names></name><name name-style="western"><surname>Kedl</surname><given-names>R. M.</given-names></name><name name-style="western"><surname>Kieper</surname><given-names>W. C.</given-names></name><name name-style="western"><surname>Qiu</surname><given-names>X.</given-names></name><etal/></person-group>. (<year>2005</year>). <article-title>Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8</article-title>. <source>J. Immunol.</source><volume>174</volume>, <fpage>1259</fpage>&#8211;<lpage>1268</lpage>. doi: <pub-id pub-id-type="doi">10.4049/jimmunol.174.3.1259</pub-id>, PMID: <pub-id pub-id-type="pmid">15661881</pub-id></mixed-citation></ref><ref id="ref46"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gosavi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Patil</surname><given-names>H. P.</given-names></name></person-group> (<year>2022</year>). <article-title>Evaluation of monophosphoryl lipid a as an adjuvanted for inactivated chikungunya virus</article-title>. <source>Vaccine</source><volume>40</volume>, <fpage>5060</fpage>&#8211;<lpage>5068</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.vaccine.2022.07.018</pub-id>, PMID: <pub-id pub-id-type="pmid">35871870</pub-id></mixed-citation></ref><ref id="ref47"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grigoryan</surname><given-names>L.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>A.</given-names></name><name name-style="western"><surname>Walls</surname><given-names>A. C.</given-names></name><name name-style="western"><surname>Lai</surname><given-names>L.</given-names></name><name name-style="western"><surname>Franco</surname><given-names>B.</given-names></name><name name-style="western"><surname>Arunachalam</surname><given-names>P. S.</given-names></name><etal/></person-group>. (<year>2022</year>). <article-title>Adjuvanting a subunit SARS-CoV-2 vaccine with clinically relevant adjuvants induces durable protection in mice</article-title>. <source>NPJ Vaccines</source><volume>7</volume>:<fpage>55</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41541-022-00472-2</pub-id>, PMID: <pub-id pub-id-type="pmid">35606518</pub-id><pub-id pub-id-type="pmcid">PMC9126867</pub-id></mixed-citation></ref><ref id="ref48"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gutjahr</surname><given-names>A.</given-names></name><name name-style="western"><surname>Papagno</surname><given-names>L.</given-names></name><name name-style="western"><surname>Vernejoul</surname><given-names>F.</given-names></name><name name-style="western"><surname>Lioux</surname><given-names>T.</given-names></name><name name-style="western"><surname>Jospin</surname><given-names>F.</given-names></name><name name-style="western"><surname>Chanut</surname><given-names>B.</given-names></name><etal/></person-group>. (<year>2020</year>). <article-title>New chimeric TLR7/NOD2 agonist is a potent adjuvant to induce mucosal immune responses</article-title>. <source>EBioMedicine</source><volume>58</volume>:<fpage>102922</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.ebiom.2020.102922</pub-id>, PMID: <pub-id pub-id-type="pmid">32739871</pub-id><pub-id pub-id-type="pmcid">PMC7393532</pub-id></mixed-citation></ref><ref id="ref49"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hajam</surname><given-names>I. A.</given-names></name><name name-style="western"><surname>Dar</surname><given-names>P. A.</given-names></name><name name-style="western"><surname>Shahnawaz</surname><given-names>I.</given-names></name><name name-style="western"><surname>Jaume</surname><given-names>J. C.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J. H.</given-names></name></person-group> (<year>2017</year>). <article-title>Bacterial flagellin-a potent immunomodulatory agent</article-title>. <source>Exp. Mol. Med.</source><volume>49</volume>:<fpage>e373</fpage>. doi: <pub-id pub-id-type="doi">10.1038/emm.2017.172</pub-id>, PMID: <pub-id pub-id-type="pmid">28860663</pub-id><pub-id pub-id-type="pmcid">PMC5628280</pub-id></mixed-citation></ref><ref id="ref50"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heitmann</surname><given-names>J. S.</given-names></name><name name-style="western"><surname>Bilich</surname><given-names>T.</given-names></name><name name-style="western"><surname>Tandler</surname><given-names>C.</given-names></name><name name-style="western"><surname>Nelde</surname><given-names>A.</given-names></name><name name-style="western"><surname>Maringer</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Marconato</surname><given-names>M.</given-names></name><etal/></person-group>. (<year>2022</year>). <article-title>A COVID-19 peptide vaccine for the induction of SARS-CoV-2 T cell immunity</article-title>. <source>Nature</source><volume>601</volume>, <fpage>617</fpage>&#8211;<lpage>622</lpage>. doi: <pub-id pub-id-type="doi">10.1038/s41586-021-04232-5</pub-id><pub-id pub-id-type="pmid">34814158</pub-id><pub-id pub-id-type="pmcid">PMC8791831</pub-id></mixed-citation></ref><ref id="ref51"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>D. L.</given-names></name><name name-style="western"><surname>Narita</surname><given-names>K.</given-names></name><name name-style="western"><surname>Hyodo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hayakawa</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Nakane</surname><given-names>A.</given-names></name><name name-style="western"><surname>Karaolis</surname><given-names>D. K.</given-names></name></person-group> (<year>2009</year>). <article-title>C-di-GMP as a vaccine adjuvant enhances protection against systemic methicillin-resistant <italic toggle="yes">Staphylococcus aureus</italic> (MRSA) infection</article-title>. <source>Vaccine</source><volume>27</volume>, <fpage>4867</fpage>&#8211;<lpage>4873</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.vaccine.2009.04.053</pub-id>, PMID: <pub-id pub-id-type="pmid">19406185</pub-id></mixed-citation></ref><ref id="ref52"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Unkeless</surname><given-names>J. C.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>Z. H.</given-names></name><name name-style="western"><surname>Xiong</surname><given-names>H.</given-names></name></person-group> (<year>2008</year>). <article-title>TLR signaling by tumor and immune cells: a double-edged sword</article-title>. <source>Oncogene</source><volume>27</volume>, <fpage>218</fpage>&#8211;<lpage>224</lpage>. doi: <pub-id pub-id-type="doi">10.1038/sj.onc.1210904</pub-id>, PMID: <pub-id pub-id-type="pmid">18176603</pub-id></mixed-citation></ref><ref id="ref53"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hussell</surname><given-names>T.</given-names></name><name name-style="western"><surname>Goenka</surname><given-names>A.</given-names></name></person-group> (<year>2016</year>). <article-title>TLR vaccine adjuvants: closing the stable door before novel influenza strains bolt?</article-title><source>Immunol. Cell Biol.</source><volume>94</volume>, <fpage>1</fpage>&#8211;<lpage>2</lpage>. doi: <pub-id pub-id-type="doi">10.1038/icb.2015.92</pub-id>, PMID: <pub-id pub-id-type="pmid">26573733</pub-id></mixed-citation></ref><ref id="ref54"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hyer</surname><given-names>R. N.</given-names></name><name name-style="western"><surname>Janssen</surname><given-names>R.</given-names></name></person-group> (<year>2018</year>). <article-title>Recently approved HEPLISAV-B(R) [hepatitis B vaccine (recombinant), Adjuvanted] shows a higher proportion of subjects achieving Seroprotection with a more consistent immune response compared with Engerix-B(R) [hepatitis B vaccine (recombinant)] in three comparative trials</article-title>. <source>Open Forum Infect. Dis.</source><volume>5</volume>, <fpage>S677</fpage>&#8211;<lpage>S678</lpage>. doi: <pub-id pub-id-type="doi">10.1093/ofid/ofy210.1940</pub-id></mixed-citation></ref><ref id="ref55"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Igietseme</surname><given-names>J. U.</given-names></name><name name-style="western"><surname>Eko</surname><given-names>F. O.</given-names></name><name name-style="western"><surname>He</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Black</surname><given-names>C. M.</given-names></name></person-group> (<year>2004</year>). <article-title>Antibody regulation of Tcell immunity: implications for vaccine strategies against intracellular pathogens</article-title>. <source>Expert Rev. Vaccines</source><volume>3</volume>, <fpage>23</fpage>&#8211;<lpage>34</lpage>. doi: <pub-id pub-id-type="doi">10.1586/14760584.3.1.23</pub-id>, PMID: <pub-id pub-id-type="pmid">14761241</pub-id></mixed-citation></ref><ref id="ref56"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Iwasaki</surname><given-names>A.</given-names></name><name name-style="western"><surname>Medzhitov</surname><given-names>R.</given-names></name></person-group> (<year>2004</year>). <article-title>Toll-like receptor control of the adaptive immune responses</article-title>. <source>Nat. Immunol.</source><volume>5</volume>, <fpage>987</fpage>&#8211;<lpage>995</lpage>. doi: <pub-id pub-id-type="doi">10.1038/ni1112</pub-id><pub-id pub-id-type="pmid">15454922</pub-id></mixed-citation></ref><ref id="ref57"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Janeway</surname><given-names>C. A.</given-names></name><name name-style="western"><surname>Medzhitov</surname><given-names>R.</given-names></name></person-group> (<year>2002</year>). <article-title>Innate immune recognition</article-title>. <source>Annu. Rev. Immunol.</source><volume>20</volume>, <fpage>197</fpage>&#8211;<lpage>216</lpage>. doi: <pub-id pub-id-type="doi">10.1146/annurev.immunol.20.083001.084359</pub-id><pub-id pub-id-type="pmid">11861602</pub-id></mixed-citation></ref><ref id="ref58"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jangra</surname><given-names>S.</given-names></name><name name-style="western"><surname>Laghlali</surname><given-names>G.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rathnasinghe</surname><given-names>R.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yildiz</surname><given-names>S.</given-names></name><etal/></person-group>. (<year>2022</year>). <article-title>RIG-I and TLR-7/8 agonists as combination adjuvant shapes unique antibody and cellular vaccine responses to seasonal influenza vaccine</article-title>. <source>Front. Immunol.</source><volume>13</volume>:<fpage>974016</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fimmu.2022.974016</pub-id>, PMID: <pub-id pub-id-type="pmid">36426358</pub-id><pub-id pub-id-type="pmcid">PMC9679288</pub-id></mixed-citation></ref><ref id="ref59"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jimenez-Leon</surname><given-names>M. R.</given-names></name><name name-style="western"><surname>Gasca-Capote</surname><given-names>C.</given-names></name><name name-style="western"><surname>Tarancon-Diez</surname><given-names>L.</given-names></name><name name-style="western"><surname>Dominguez-Molina</surname><given-names>B.</given-names></name><name name-style="western"><surname>Lopez-Verdugo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ritraj</surname><given-names>R.</given-names></name><etal/></person-group>. (<year>2023</year>). <article-title>Toll-like receptor agonists enhance HIV-specific T cell response mediated by plasmacytoid dendritic cells in diverse HIV-1 disease progression phenotypes</article-title>. <source>EBioMedicine</source><volume>91</volume>:<fpage>104549</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.ebiom.2023.104549</pub-id>, PMID: <pub-id pub-id-type="pmid">37018973</pub-id><pub-id pub-id-type="pmcid">PMC10106920</pub-id></mixed-citation></ref><ref id="ref60"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaczanowska</surname><given-names>S.</given-names></name><name name-style="western"><surname>Joseph</surname><given-names>A. M.</given-names></name><name name-style="western"><surname>Davila</surname><given-names>E.</given-names></name></person-group> (<year>2013</year>). <article-title>TLR agonists: our best frenemy in cancer immunotherapy</article-title>. <source>J. Leukoc. Biol.</source><volume>93</volume>, <fpage>847</fpage>&#8211;<lpage>863</lpage>. doi: <pub-id pub-id-type="doi">10.1189/jlb.1012501</pub-id><pub-id pub-id-type="pmid">23475577</pub-id><pub-id pub-id-type="pmcid">PMC3656332</pub-id></mixed-citation></ref><ref id="ref61"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kasturi</surname><given-names>S. P.</given-names></name><name name-style="western"><surname>Rasheed</surname><given-names>M. A. U.</given-names></name><name name-style="western"><surname>Havenar-Daughton</surname><given-names>C.</given-names></name><name name-style="western"><surname>Pham</surname><given-names>M.</given-names></name><name name-style="western"><surname>Legere</surname><given-names>T.</given-names></name><name name-style="western"><surname>Sher</surname><given-names>Z. J.</given-names></name><etal/></person-group>. (<year>2020</year>). <article-title>3M-052, a synthetic TLR-7/8 agonist, induces durable HIV-1 envelope-specific plasma cells and humoral immunity in nonhuman primates</article-title>. <source>Sci Immunol</source><volume>5</volume>:<fpage>1025</fpage>. doi: <pub-id pub-id-type="doi">10.1126/sciimmunol.abb1025</pub-id>, PMID: <pub-id pub-id-type="pmid">32561559</pub-id><pub-id pub-id-type="pmcid">PMC8109745</pub-id></mixed-citation></ref><ref id="ref62"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kato</surname><given-names>H.</given-names></name><name name-style="western"><surname>Takeuchi</surname><given-names>O.</given-names></name><name name-style="western"><surname>Sato</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yoneyama</surname><given-names>M.</given-names></name><name name-style="western"><surname>Yamamoto</surname><given-names>M.</given-names></name><name name-style="western"><surname>Matsui</surname><given-names>K.</given-names></name><etal/></person-group>. (<year>2006</year>). <article-title>Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses</article-title>. <source>Nature</source><volume>441</volume>, <fpage>101</fpage>&#8211;<lpage>105</lpage>. doi: <pub-id pub-id-type="doi">10.1038/nature04734</pub-id><pub-id pub-id-type="pmid">16625202</pub-id></mixed-citation></ref><ref id="ref63"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaushik</surname><given-names>D.</given-names></name><name name-style="western"><surname>Dhingra</surname><given-names>S.</given-names></name><name name-style="western"><surname>Patil</surname><given-names>M. T.</given-names></name><name name-style="western"><surname>Piplani</surname><given-names>S.</given-names></name><name name-style="western"><surname>Khanna</surname><given-names>V.</given-names></name><name name-style="western"><surname>Honda-Okubo</surname><given-names>Y.</given-names></name><etal/></person-group>. (<year>2020</year>). <article-title>BBIQ, a pure TLR7 agonist, is an effective influenza vaccine adjuvant</article-title>. <source>Hum. Vaccin. Immunother.</source><volume>16</volume>, <fpage>1989</fpage>&#8211;<lpage>1996</lpage>. doi: <pub-id pub-id-type="doi">10.1080/21645515.2019.1710409</pub-id>, PMID: <pub-id pub-id-type="pmid">32298200</pub-id><pub-id pub-id-type="pmcid">PMC7482670</pub-id></mixed-citation></ref><ref id="ref64"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kawai</surname><given-names>T.</given-names></name><name name-style="western"><surname>Akira</surname><given-names>S.</given-names></name></person-group> (<year>2006</year>). <article-title>TLR signaling</article-title>. <source>Cell Death Differ.</source><volume>13</volume>, <fpage>816</fpage>&#8211;<lpage>825</lpage>. doi: <pub-id pub-id-type="doi">10.1038/sj.cdd.4401850</pub-id><pub-id pub-id-type="pmid">16410796</pub-id></mixed-citation></ref><ref id="ref65"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kawai</surname><given-names>T.</given-names></name><name name-style="western"><surname>Akira</surname><given-names>S.</given-names></name></person-group> (<year>2009</year>). <article-title>The roles of TLRs, RLRs and NLRs in pathogen recognition</article-title>. <source>Int. Immunol.</source><volume>21</volume>, <fpage>317</fpage>&#8211;<lpage>337</lpage>. doi: <pub-id pub-id-type="doi">10.1093/intimm/dxp017</pub-id>, PMID: <pub-id pub-id-type="pmid">19246554</pub-id><pub-id pub-id-type="pmcid">PMC2721684</pub-id></mixed-citation></ref><ref id="ref66"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kawai</surname><given-names>T.</given-names></name><name name-style="western"><surname>Akira</surname><given-names>S.</given-names></name></person-group> (<year>2010</year>). <article-title>The role of pattern-recognition receptors in innate immunity: update on toll-like receptors</article-title>. <source>Nat. Immunol.</source><volume>11</volume>, <fpage>373</fpage>&#8211;<lpage>384</lpage>. doi: <pub-id pub-id-type="doi">10.1038/ni.1863</pub-id><pub-id pub-id-type="pmid">20404851</pub-id></mixed-citation></ref><ref id="ref67"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kayesh</surname><given-names>M. E. H.</given-names></name><name name-style="western"><surname>Ezzikouri</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Sanada</surname><given-names>T.</given-names></name><name name-style="western"><surname>Yamamoto</surname><given-names>N.</given-names></name><name name-style="western"><surname>Kitab</surname><given-names>B.</given-names></name><etal/></person-group>. (<year>2017a</year>). <article-title>Interferon-beta response is impaired by hepatitis B virus infection in <italic toggle="yes">Tupaia belangeri</italic></article-title>. <source>Virus Res.</source><volume>237</volume>, <fpage>47</fpage>&#8211;<lpage>57</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.virusres.2017.05.013</pub-id>, PMID: <pub-id pub-id-type="pmid">28551415</pub-id></mixed-citation></ref><ref id="ref68"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kayesh</surname><given-names>M. E. H.</given-names></name><name name-style="western"><surname>Ezzikouri</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sanada</surname><given-names>T.</given-names></name><name name-style="western"><surname>Chi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Hayashi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Rebbani</surname><given-names>K.</given-names></name><etal/></person-group>. (<year>2017b</year>). <article-title>Oxidative stress and immune responses during hepatitis C virus infection in <italic toggle="yes">Tupaia belangeri</italic></article-title>. <source>Sci. Rep.</source><volume>7</volume>:<fpage>9848</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41598-017-10329-7</pub-id>, PMID: <pub-id pub-id-type="pmid">28852124</pub-id><pub-id pub-id-type="pmcid">PMC5575003</pub-id></mixed-citation></ref><ref id="ref69"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kayesh</surname><given-names>M. E. H.</given-names></name><name name-style="western"><surname>Kohara</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tsukiyama-Kohara</surname><given-names>K.</given-names></name></person-group> (<year>2021a</year>). <article-title>An overview of recent insights into the response of TLR to SARS-CoV-2 infection and the potential of TLR agonists as SARS-CoV-2 vaccine adjuvants</article-title>. <source>Viruses</source><volume>13</volume>:<fpage>302</fpage>. doi: <pub-id pub-id-type="doi">10.3390/v13112302</pub-id>, PMID: <pub-id pub-id-type="pmid">34835108</pub-id><pub-id pub-id-type="pmcid">PMC8622245</pub-id></mixed-citation></ref><ref id="ref70"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kayesh</surname><given-names>M. E. H.</given-names></name><name name-style="western"><surname>Kohara</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tsukiyama-Kohara</surname><given-names>K.</given-names></name></person-group> (<year>2021b</year>). <article-title>Recent insights into the molecular mechanism of toll-like receptor response to dengue virus infection</article-title>. <source>Front. Microbiol.</source><volume>12</volume>:<fpage>744233</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fmicb.2021.744233</pub-id><pub-id pub-id-type="pmid">34603272</pub-id><pub-id pub-id-type="pmcid">PMC8483762</pub-id></mixed-citation></ref><ref id="ref71"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kayesh</surname><given-names>M. E. H.</given-names></name><name name-style="western"><surname>Kohara</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tsukiyama-Kohara</surname><given-names>K.</given-names></name></person-group> (<year>2021c</year>). <article-title>Toll-like receptor response to hepatitis B virus infection and potential of TLR agonists as Immunomodulators for treating chronic hepatitis B: an overview</article-title>. <source>Int. J. Mol. Sci.</source><volume>22</volume>:<fpage>462</fpage>. doi: <pub-id pub-id-type="doi">10.3390/ijms221910462</pub-id>, PMID: <pub-id pub-id-type="pmid">34638802</pub-id><pub-id pub-id-type="pmcid">PMC8508807</pub-id></mixed-citation></ref><ref id="ref72"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kayesh</surname><given-names>M. E. H.</given-names></name><name name-style="western"><surname>Kohara</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tsukiyama-Kohara</surname><given-names>K.</given-names></name></person-group> (<year>2022</year>). <article-title>Toll-like receptor response to hepatitis C virus infection: a recent overview</article-title>. <source>Int. J. Mol. Sci.</source><volume>23</volume>:<fpage>5475</fpage>. doi: <pub-id pub-id-type="doi">10.3390/ijms23105475</pub-id>, PMID: <pub-id pub-id-type="pmid">35628287</pub-id><pub-id pub-id-type="pmcid">PMC9141274</pub-id></mixed-citation></ref><ref id="ref73"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kayesh</surname><given-names>M. E. H.</given-names></name><name name-style="western"><surname>Kohara</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tsukiyama-Kohara</surname><given-names>K.</given-names></name></person-group> (<year>2023</year>). <article-title>Toll-like receptor response to human immunodeficiency virus type 1 or co-infection with hepatitis B or C virus: an overview</article-title>. <source>Int. J. Mol. Sci.</source><volume>24</volume>:<fpage>9624</fpage>. doi: <pub-id pub-id-type="doi">10.3390/ijms24119624</pub-id>, PMID: <pub-id pub-id-type="pmid">37298575</pub-id><pub-id pub-id-type="pmcid">PMC10253624</pub-id></mixed-citation></ref><ref id="ref74"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kundi</surname><given-names>M.</given-names></name></person-group> (<year>2007</year>). <article-title>New hepatitis B vaccine formulated with an improved adjuvant system</article-title>. <source>Expert Rev. Vaccines</source><volume>6</volume>, <fpage>133</fpage>&#8211;<lpage>140</lpage>. doi: <pub-id pub-id-type="doi">10.1586/14760584.6.2.133</pub-id><pub-id pub-id-type="pmid">17408363</pub-id></mixed-citation></ref><ref id="ref75"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>S. M.</given-names></name><name name-style="western"><surname>Kok</surname><given-names>K. H.</given-names></name><name name-style="western"><surname>Jaume</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cheung</surname><given-names>T. K.</given-names></name><name name-style="western"><surname>Yip</surname><given-names>T. F.</given-names></name><name name-style="western"><surname>Lai</surname><given-names>J. C.</given-names></name><etal/></person-group>. (<year>2014</year>). <article-title>Toll-like receptor 10 is involved in induction of innate immune responses to influenza virus infection</article-title>. <source>Proc. Natl. Acad. Sci. U. S. A.</source><volume>111</volume>, <fpage>3793</fpage>&#8211;<lpage>3798</lpage>. doi: <pub-id pub-id-type="doi">10.1073/pnas.1324266111</pub-id>, PMID: <pub-id pub-id-type="pmid">24567377</pub-id><pub-id pub-id-type="pmcid">PMC3956146</pub-id></mixed-citation></ref><ref id="ref76"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>G. H.</given-names></name><name name-style="western"><surname>Lim</surname><given-names>S. G.</given-names></name></person-group> (<year>2021</year>). <article-title>CpG-Adjuvanted hepatitis B vaccine (HEPLISAV-B(R)) update</article-title>. <source>Expert Rev. Vaccines</source><volume>20</volume>, <fpage>487</fpage>&#8211;<lpage>495</lpage>. doi: <pub-id pub-id-type="doi">10.1080/14760584.2021.1908133</pub-id><pub-id pub-id-type="pmid">33783302</pub-id></mixed-citation></ref><ref id="ref77"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>G.</given-names></name><name name-style="western"><surname>De Clercq</surname><given-names>E.</given-names></name></person-group> (<year>2017</year>). <article-title>Current therapy for chronic hepatitis C: the role of direct-acting antivirals</article-title>. <source>Antiviral Res.</source><volume>142</volume>, <fpage>83</fpage>&#8211;<lpage>122</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.antiviral.2017.02.014</pub-id>, PMID: <pub-id pub-id-type="pmid">28238877</pub-id><pub-id pub-id-type="pmcid">PMC7172984</pub-id></mixed-citation></ref><ref id="ref78"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Tarbet</surname><given-names>B.</given-names></name><name name-style="western"><surname>Song</surname><given-names>L.</given-names></name><name name-style="western"><surname>Reiserova</surname><given-names>L.</given-names></name><name name-style="western"><surname>Weaver</surname><given-names>B.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><etal/></person-group>. (<year>2011</year>). <article-title>Immunogenicity and efficacy of flagellin-fused vaccine candidates targeting 2009 pandemic H1N1 influenza in mice</article-title>. <source>PloS One</source><volume>6</volume>:<fpage>e20928</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0020928</pub-id>, PMID: <pub-id pub-id-type="pmid">21687743</pub-id><pub-id pub-id-type="pmcid">PMC3110246</pub-id></mixed-citation></ref><ref id="ref79"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Yao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Qi</surname><given-names>H.</given-names></name></person-group> (<year>2022</year>). <article-title>Heterogeneous plasma cells and long-lived subsets in response to immunization, autoantigen and microbiota</article-title>. <source>Nat. Immunol.</source><volume>23</volume>, <fpage>1564</fpage>&#8211;<lpage>1576</lpage>. doi: <pub-id pub-id-type="doi">10.1038/s41590-022-01345-5</pub-id>, PMID: <pub-id pub-id-type="pmid">36316480</pub-id></mixed-citation></ref><ref id="ref80"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lopez</surname><given-names>A. M.</given-names></name><name name-style="western"><surname>Hecker</surname><given-names>R.</given-names></name><name name-style="western"><surname>Mutwiri</surname><given-names>G.</given-names></name><name name-style="western"><surname>Drunen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Babiuk</surname><given-names>L. A.</given-names></name><name name-style="western"><surname>Townsend</surname><given-names>H. G.</given-names></name></person-group> (<year>2006</year>). <article-title>Formulation with CpG ODN enhances antibody responses to an equine influenza virus vaccine</article-title>. <source>Vet. Immunol. Immunopathol.</source><volume>114</volume>, <fpage>103</fpage>&#8211;<lpage>110</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.vetimm.2006.07.013</pub-id>, PMID: <pub-id pub-id-type="pmid">16950519</pub-id></mixed-citation></ref><ref id="ref81"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>P. D.</given-names></name></person-group> (<year>2012</year>). <article-title>The structure of the TLR5-flagellin complex: a new mode of pathogen detection, conserved receptor dimerization for signaling</article-title>. <source>Sci. Signal.</source><volume>5</volume>:<fpage>pe11</fpage>. doi: <pub-id pub-id-type="doi">10.1126/scisignal.2002963</pub-id>, PMID: <pub-id pub-id-type="pmid">22434932</pub-id></mixed-citation></ref><ref id="ref82"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luchner</surname><given-names>M.</given-names></name><name name-style="western"><surname>Reinke</surname><given-names>S.</given-names></name><name name-style="western"><surname>Milicic</surname><given-names>A.</given-names></name></person-group> (<year>2021</year>). <article-title>TLR agonists as vaccine adjuvants targeting Cancer and infectious diseases</article-title>. <source>Pharmaceutics</source><volume>13</volume>:<fpage>142</fpage>. doi: <pub-id pub-id-type="doi">10.3390/pharmaceutics13020142</pub-id><pub-id pub-id-type="pmid">33499143</pub-id><pub-id pub-id-type="pmcid">PMC7911620</pub-id></mixed-citation></ref><ref id="ref83"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Magalhaes</surname><given-names>J. G.</given-names></name><name name-style="western"><surname>Fritz</surname><given-names>J. H.</given-names></name><name name-style="western"><surname>Le Bourhis</surname><given-names>L.</given-names></name><name name-style="western"><surname>Sellge</surname><given-names>G.</given-names></name><name name-style="western"><surname>Travassos</surname><given-names>L. H.</given-names></name><name name-style="western"><surname>Selvanantham</surname><given-names>T.</given-names></name><etal/></person-group>. (<year>2008</year>). <article-title>Nod2-dependent Th2 polarization of antigen-specific immunity</article-title>. <source>J. Immunol.</source><volume>181</volume>, <fpage>7925</fpage>&#8211;<lpage>7935</lpage>. doi: <pub-id pub-id-type="doi">10.4049/jimmunol.181.11.7925</pub-id>, PMID: <pub-id pub-id-type="pmid">19017983</pub-id></mixed-citation></ref><ref id="ref84"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Magalhaes</surname><given-names>J. G.</given-names></name><name name-style="western"><surname>Rubino</surname><given-names>S. J.</given-names></name><name name-style="western"><surname>Travassos</surname><given-names>L. H.</given-names></name><name name-style="western"><surname>Le Bourhis</surname><given-names>L.</given-names></name><name name-style="western"><surname>Duan</surname><given-names>W.</given-names></name><name name-style="western"><surname>Sellge</surname><given-names>G.</given-names></name><etal/></person-group>. (<year>2011</year>). <article-title>Nucleotide oligomerization domain-containing proteins instruct T cell helper type 2 immunity through stromal activation</article-title>. <source>Proc. Natl. Acad. Sci. U. S. A.</source><volume>108</volume>, <fpage>14896</fpage>&#8211;<lpage>14901</lpage>. doi: <pub-id pub-id-type="doi">10.1073/pnas.1015063108</pub-id>, PMID: <pub-id pub-id-type="pmid">21856952</pub-id><pub-id pub-id-type="pmcid">PMC3169112</pub-id></mixed-citation></ref><ref id="ref85"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maisonneuve</surname><given-names>C.</given-names></name><name name-style="western"><surname>Bertholet</surname><given-names>S.</given-names></name><name name-style="western"><surname>Philpott</surname><given-names>D. J.</given-names></name><name name-style="western"><surname>De Gregorio</surname><given-names>E.</given-names></name></person-group> (<year>2014</year>). <article-title>Unleashing the potential of NOD- and Toll-like agonists as vaccine adjuvants</article-title>. <source>Proc. Natl. Acad. Sci. U. S. A.</source><volume>111</volume>, <fpage>12294</fpage>&#8211;<lpage>12299</lpage>. doi: <pub-id pub-id-type="doi">10.1073/pnas.1400478111</pub-id>, PMID: <pub-id pub-id-type="pmid">25136133</pub-id><pub-id pub-id-type="pmcid">PMC4151741</pub-id></mixed-citation></ref><ref id="ref86"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marks</surname><given-names>K. M.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Umbleja</surname><given-names>T.</given-names></name><name name-style="western"><surname>Avihingsanon</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sugandhavesa</surname><given-names>P.</given-names></name><name name-style="western"><surname>Cox</surname><given-names>A. L.</given-names></name><etal/></person-group>. (<year>2023</year>). <article-title>Immunogenicity and safety of hepatitis B vaccine with a toll-like receptor 9 agonist adjuvant (HEPLISAV-B) in HBV vaccine-naive people with HIV</article-title>. <source>Clin. Infect. Dis.</source><volume>77</volume>, <fpage>414</fpage>&#8211;<lpage>418</lpage>. doi: <pub-id pub-id-type="doi">10.1093/cid/ciad201</pub-id><pub-id pub-id-type="pmid">37017075</pub-id><pub-id pub-id-type="pmcid">PMC10681652</pub-id></mixed-citation></ref><ref id="ref87"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Martinsen</surname><given-names>J. T.</given-names></name><name name-style="western"><surname>Gunst</surname><given-names>J. D.</given-names></name><name name-style="western"><surname>Hojen</surname><given-names>J. F.</given-names></name><name name-style="western"><surname>Tolstrup</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sogaard</surname><given-names>O. S.</given-names></name></person-group> (<year>2020</year>). <article-title>The use of toll-like receptor agonists in HIV-1 cure strategies</article-title>. <source>Front. Immunol.</source><volume>11</volume>:<fpage>1112</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fimmu.2020.01112</pub-id>, PMID: <pub-id pub-id-type="pmid">32595636</pub-id><pub-id pub-id-type="pmcid">PMC7300204</pub-id></mixed-citation></ref><ref id="ref88"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mattei</surname><given-names>F.</given-names></name><name name-style="western"><surname>Schiavoni</surname><given-names>G.</given-names></name><name name-style="western"><surname>Belardelli</surname><given-names>F.</given-names></name><name name-style="western"><surname>Tough</surname><given-names>D. F.</given-names></name></person-group> (<year>2001</year>). <article-title>IL-15 is expressed by dendritic cells in response to type I IFN, double-stranded RNA, or lipopolysaccharide and promotes dendritic cell activation</article-title>. <source>J. Immunol.</source><volume>167</volume>, <fpage>1179</fpage>&#8211;<lpage>1187</lpage>. doi: <pub-id pub-id-type="doi">10.4049/jimmunol.167.3.1179</pub-id><pub-id pub-id-type="pmid">11466332</pub-id></mixed-citation></ref><ref id="ref89"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mcdonald</surname><given-names>W. F.</given-names></name><name name-style="western"><surname>Huleatt</surname><given-names>J. W.</given-names></name><name name-style="western"><surname>Foellmer</surname><given-names>H. G.</given-names></name><name name-style="western"><surname>Hewitt</surname><given-names>D.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Desai</surname><given-names>P.</given-names></name><etal/></person-group>. (<year>2007</year>). <article-title>A West Nile virus recombinant protein vaccine that coactivates innate and adaptive immunity</article-title>. <source>J Infect Dis</source><volume>195</volume>, <fpage>1607</fpage>&#8211;<lpage>1617</lpage>. doi: <pub-id pub-id-type="doi">10.1086/517613</pub-id>, PMID: <pub-id pub-id-type="pmid">17471430</pub-id></mixed-citation></ref><ref id="ref90"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mchutchison</surname><given-names>J. G.</given-names></name><name name-style="western"><surname>Bacon</surname><given-names>B. R.</given-names></name><name name-style="western"><surname>Gordon</surname><given-names>S. C.</given-names></name><name name-style="western"><surname>Lawitz</surname><given-names>E.</given-names></name><name name-style="western"><surname>Shiffman</surname><given-names>M.</given-names></name><name name-style="western"><surname>Afdhal</surname><given-names>N. H.</given-names></name><etal/></person-group>. (<year>2007</year>). <article-title>Phase 1B, randomized, double-blind, dose-escalation trial of CPG 10101 in patients with chronic hepatitis C virus</article-title>. <source>Hepatology</source><volume>46</volume>, <fpage>1341</fpage>&#8211;<lpage>1349</lpage>. doi: <pub-id pub-id-type="doi">10.1002/hep.21773</pub-id>, PMID: <pub-id pub-id-type="pmid">17929306</pub-id></mixed-citation></ref><ref id="ref91"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Medzhitov</surname><given-names>R.</given-names></name><name name-style="western"><surname>Janeway</surname><given-names>C.</given-names></name></person-group> (<year>2000</year>). <article-title>Innate immunity</article-title>. <source>N. Engl. J. Med.</source><volume>343</volume>, <fpage>338</fpage>&#8211;<lpage>344</lpage>. doi: <pub-id pub-id-type="doi">10.1056/NEJM200008033430506</pub-id><pub-id pub-id-type="pmid">10922424</pub-id></mixed-citation></ref><ref id="ref92"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mogensen</surname><given-names>T. H.</given-names></name></person-group> (<year>2009</year>). <article-title>Pathogen recognition and inflammatory signaling in innate immune defenses</article-title>. <source>Clin. Microbiol. Rev.</source><volume>22</volume>, <fpage>240</fpage>&#8211;<lpage>273</lpage>. doi: <pub-id pub-id-type="doi">10.1128/CMR.00046-08</pub-id>, PMID: <pub-id pub-id-type="pmid">19366914</pub-id><pub-id pub-id-type="pmcid">PMC2668232</pub-id></mixed-citation></ref><ref id="ref93"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moody</surname><given-names>M. A.</given-names></name><name name-style="western"><surname>Santra</surname><given-names>S.</given-names></name><name name-style="western"><surname>Vandergrift</surname><given-names>N. A.</given-names></name><name name-style="western"><surname>Sutherland</surname><given-names>L. L.</given-names></name><name name-style="western"><surname>Gurley</surname><given-names>T. C.</given-names></name><name name-style="western"><surname>Drinker</surname><given-names>M. S.</given-names></name><etal/></person-group>. (<year>2014</year>). <article-title>Toll-like receptor 7/8 (TLR7/8) and TLR9 agonists cooperate to enhance HIV-1 envelope antibody responses in rhesus macaques</article-title>. <source>J. Virol.</source><volume>88</volume>, <fpage>3329</fpage>&#8211;<lpage>3339</lpage>. doi: <pub-id pub-id-type="doi">10.1128/JVI.03309-13</pub-id>, PMID: <pub-id pub-id-type="pmid">24390332</pub-id><pub-id pub-id-type="pmcid">PMC3957956</pub-id></mixed-citation></ref><ref id="ref94"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mullins</surname><given-names>S. R.</given-names></name><name name-style="western"><surname>Vasilakos</surname><given-names>J. P.</given-names></name><name name-style="western"><surname>Deschler</surname><given-names>K.</given-names></name><name name-style="western"><surname>Grigsby</surname><given-names>I.</given-names></name><name name-style="western"><surname>Gillis</surname><given-names>P.</given-names></name><name name-style="western"><surname>John</surname><given-names>J.</given-names></name><etal/></person-group>. (<year>2019</year>). <article-title>Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies</article-title>. <source>J. Immunother. Cancer</source><volume>7</volume>:<fpage>244</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s40425-019-0724-8</pub-id>, PMID: <pub-id pub-id-type="pmid">31511088</pub-id><pub-id pub-id-type="pmcid">PMC6739946</pub-id></mixed-citation></ref><ref id="ref95"><mixed-citation publication-type="other"><person-group person-group-type="author"><collab id="coll2">National Institutes of Health</collab></person-group> (<year>2022</year>). Three-dose hepatitis B vaccine regimen protects people with HIV. News Release on. Available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.nih.gov/news-events/news-releases/three-dose-hepatitis-b-vaccine-regimen-protects-people-hiv" ext-link-type="uri">https://www.nih.gov/news-events/news-releases/three-dose-hepatitis-b-vaccine-regimen-protects-people-hiv</ext-link> (Accessed 11 November 2023).</mixed-citation></ref><ref id="ref96"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ogunniyi</surname><given-names>A. D.</given-names></name><name name-style="western"><surname>Paton</surname><given-names>J. C.</given-names></name><name name-style="western"><surname>Kirby</surname><given-names>A. C.</given-names></name><name name-style="western"><surname>Mccullers</surname><given-names>J. A.</given-names></name><name name-style="western"><surname>Cook</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hyodo</surname><given-names>M.</given-names></name><etal/></person-group>. (<year>2008</year>). <article-title>C-di-GMP is an effective immunomodulator and vaccine adjuvant against pneumococcal infection</article-title>. <source>Vaccine</source><volume>26</volume>, <fpage>4676</fpage>&#8211;<lpage>4685</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.vaccine.2008.06.099</pub-id>, PMID: <pub-id pub-id-type="pmid">18640167</pub-id><pub-id pub-id-type="pmcid">PMC2647696</pub-id></mixed-citation></ref><ref id="ref97"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oleszycka</surname><given-names>E.</given-names></name><name name-style="western"><surname>Mccluskey</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sharp</surname><given-names>F. A.</given-names></name><name name-style="western"><surname>Munoz-Wolf</surname><given-names>N.</given-names></name><name name-style="western"><surname>Hams</surname><given-names>E.</given-names></name><name name-style="western"><surname>Gorman</surname><given-names>A. L.</given-names></name><etal/></person-group>. (<year>2018</year>). <article-title>The vaccine adjuvant alum promotes IL-10 production that suppresses Th1 responses</article-title>. <source>Eur. J. Immunol.</source><volume>48</volume>, <fpage>705</fpage>&#8211;<lpage>715</lpage>. doi: <pub-id pub-id-type="doi">10.1002/eji.201747150</pub-id>, PMID: <pub-id pub-id-type="pmid">29349774</pub-id></mixed-citation></ref><ref id="ref98"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pillet</surname><given-names>S.</given-names></name><name name-style="western"><surname>Aubin</surname><given-names>E.</given-names></name><name name-style="western"><surname>Trepanier</surname><given-names>S.</given-names></name><name name-style="western"><surname>Poulin</surname><given-names>J. F.</given-names></name><name name-style="western"><surname>Yassine-Diab</surname><given-names>B.</given-names></name><name name-style="western"><surname>Ter Meulen</surname><given-names>J.</given-names></name><etal/></person-group>. (<year>2018</year>). <article-title>Humoral and cell-mediated immune responses to H5N1 plant-made virus-like particle vaccine are differentially impacted by alum and GLA-SE adjuvants in a phase 2 clinical trial</article-title>. <source>NPJ Vaccines</source><volume>3</volume>:<fpage>3</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41541-017-0043-3</pub-id>, PMID: <pub-id pub-id-type="pmid">29387473</pub-id><pub-id pub-id-type="pmcid">PMC5780465</pub-id></mixed-citation></ref><ref id="ref99"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Proud</surname><given-names>P. C.</given-names></name><name name-style="western"><surname>Tsitoura</surname><given-names>D.</given-names></name><name name-style="western"><surname>Watson</surname><given-names>R. J.</given-names></name><name name-style="western"><surname>Chua</surname><given-names>B. Y.</given-names></name><name name-style="western"><surname>Aram</surname><given-names>M. J.</given-names></name><name name-style="western"><surname>Bewley</surname><given-names>K. R.</given-names></name><etal/></person-group>. (<year>2021</year>). <article-title>Prophylactic intranasal administration of a TLR2/6 agonist reduces upper respiratory tract viral shedding in a SARS-CoV-2 challenge ferret model</article-title>. <source>EBioMedicine</source><volume>63</volume>:<fpage>103153</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.ebiom.2020.103153</pub-id><pub-id pub-id-type="pmid">33279857</pub-id><pub-id pub-id-type="pmcid">PMC7711201</pub-id></mixed-citation></ref><ref id="ref100"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pulendran</surname><given-names>B.</given-names></name><name name-style="western"><surname>O'hagan</surname><given-names>D. T.</given-names></name></person-group> (<year>2021</year>). <article-title>Emerging concepts in the science of vaccine adjuvants</article-title>. <source>Nat. Rev. Drug Discov.</source><volume>20</volume>, <fpage>454</fpage>&#8211;<lpage>475</lpage>. doi: <pub-id pub-id-type="doi">10.1038/s41573-021-00163-y</pub-id>, PMID: <pub-id pub-id-type="pmid">33824489</pub-id><pub-id pub-id-type="pmcid">PMC8023785</pub-id></mixed-citation></ref><ref id="ref101"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reed</surname><given-names>S. G.</given-names></name><name name-style="western"><surname>Orr</surname><given-names>M. T.</given-names></name><name name-style="western"><surname>Fox</surname><given-names>C. B.</given-names></name></person-group> (<year>2013</year>). <article-title>Key roles of adjuvants in modern vaccines</article-title>. <source>Nat. Med.</source><volume>19</volume>, <fpage>1597</fpage>&#8211;<lpage>1608</lpage>. doi: <pub-id pub-id-type="doi">10.1038/nm.3409</pub-id>, PMID: <pub-id pub-id-type="pmid">24309663</pub-id></mixed-citation></ref><ref id="ref102"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rozman</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zidovec-Lepej</surname><given-names>S.</given-names></name><name name-style="western"><surname>Jambrosic</surname><given-names>K.</given-names></name><name name-style="western"><surname>Babic</surname><given-names>M.</given-names></name><name name-style="western"><surname>Drmic Hofman</surname><given-names>I.</given-names></name></person-group> (<year>2023</year>). <article-title>Role of TLRs in HIV-1 infection and potential of TLR agonists in HIV-1 vaccine development and treatment strategies</article-title>. <source>Pathogens</source><volume>12</volume>:<fpage>92</fpage>. doi: <pub-id pub-id-type="doi">10.3390/pathogens12010092</pub-id>, PMID: <pub-id pub-id-type="pmid">36678440</pub-id><pub-id pub-id-type="pmcid">PMC9866513</pub-id></mixed-citation></ref><ref id="ref103"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Salaun</surname><given-names>B.</given-names></name><name name-style="western"><surname>Romero</surname><given-names>P.</given-names></name><name name-style="western"><surname>Lebecque</surname><given-names>S.</given-names></name></person-group> (<year>2007</year>). <article-title>Toll-like receptors' two-edged sword: when immunity meets apoptosis</article-title>. <source>Eur. J. Immunol.</source><volume>37</volume>, <fpage>3311</fpage>&#8211;<lpage>3318</lpage>. doi: <pub-id pub-id-type="doi">10.1002/eji.200737744</pub-id>, PMID: <pub-id pub-id-type="pmid">18034428</pub-id></mixed-citation></ref><ref id="ref104"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sato-Kaneko</surname><given-names>F.</given-names></name><name name-style="western"><surname>Yao</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lao</surname><given-names>F. S.</given-names></name><name name-style="western"><surname>Shpigelman</surname><given-names>J.</given-names></name><name name-style="western"><surname>Messer</surname><given-names>K.</given-names></name><name name-style="western"><surname>Pu</surname><given-names>M.</given-names></name><etal/></person-group>. (<year>2020</year>). <article-title>A novel synthetic dual agonistic liposomal TLR4/7 adjuvant promotes broad immune responses in an influenza vaccine with minimal Reactogenicity</article-title>. <source>Front. Immunol.</source><volume>11</volume>:<fpage>1207</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fimmu.2020.01207</pub-id>, PMID: <pub-id pub-id-type="pmid">32636840</pub-id><pub-id pub-id-type="pmcid">PMC7318308</pub-id></mixed-citation></ref><ref id="ref105"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schneider</surname><given-names>M.</given-names></name><name name-style="western"><surname>Narciso-Abraham</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hadl</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mcmahon</surname><given-names>R.</given-names></name><name name-style="western"><surname>Toepfer</surname><given-names>S.</given-names></name><name name-style="western"><surname>Fuchs</surname><given-names>U.</given-names></name><etal/></person-group>. (<year>2023</year>). <article-title>Safety and immunogenicity of a single-shot live-attenuated chikungunya vaccine: a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial</article-title>. <source>Lancet</source><volume>401</volume>, <fpage>2138</fpage>&#8211;<lpage>2147</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0140-6736(23)00641-4</pub-id>, PMID: <pub-id pub-id-type="pmid">37321235</pub-id><pub-id pub-id-type="pmcid">PMC10314240</pub-id></mixed-citation></ref><ref id="ref106"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Silva</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kato</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Melo</surname><given-names>M. B.</given-names></name><name name-style="western"><surname>Phung</surname><given-names>I.</given-names></name><name name-style="western"><surname>Freeman</surname><given-names>B. L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z.</given-names></name><etal/></person-group>. (<year>2021</year>). <article-title>A particulate saponin/TLR agonist vaccine adjuvant alters lymph flow and modulates adaptive immunity</article-title>. <source>Sci Immunol</source><volume>6</volume>:<fpage>eabf1152</fpage>. doi: <pub-id pub-id-type="doi">10.1126/sciimmunol.abf1152</pub-id><pub-id pub-id-type="pmid">34860581</pub-id><pub-id pub-id-type="pmcid">PMC8763571</pub-id></mixed-citation></ref><ref id="ref107"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Song</surname><given-names>L.</given-names></name><name name-style="western"><surname>Nakaar</surname><given-names>V.</given-names></name><name name-style="western"><surname>Kavita</surname><given-names>U.</given-names></name><name name-style="western"><surname>Price</surname><given-names>A.</given-names></name><name name-style="western"><surname>Huleatt</surname><given-names>J.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>J.</given-names></name><etal/></person-group>. (<year>2008</year>). <article-title>Efficacious recombinant influenza vaccines produced by high yield bacterial expression: a solution to global pandemic and seasonal needs</article-title>. <source>PloS One</source><volume>3</volume>:<fpage>e2257</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0002257</pub-id>, PMID: <pub-id pub-id-type="pmid">18493310</pub-id><pub-id pub-id-type="pmcid">PMC2373928</pub-id></mixed-citation></ref><ref id="ref108"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sukriti</surname><given-names>S.</given-names></name><name name-style="western"><surname>Pati</surname><given-names>N. T.</given-names></name><name name-style="western"><surname>Bose</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hissar</surname><given-names>S. S.</given-names></name><name name-style="western"><surname>Sarin</surname><given-names>S. K.</given-names></name></person-group> (<year>2010</year>). <article-title>Impaired antigen processing and presentation machinery is associated with immunotolerant state in chronic hepatitis B virus infection</article-title>. <source>J. Clin. Immunol.</source><volume>30</volume>, <fpage>419</fpage>&#8211;<lpage>425</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s10875-010-9379-4</pub-id><pub-id pub-id-type="pmid">20300807</pub-id></mixed-citation></ref><ref id="ref109"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Surendran</surname><given-names>N.</given-names></name><name name-style="western"><surname>Simmons</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pichichero</surname><given-names>M. E.</given-names></name></person-group> (<year>2018</year>). <article-title>TLR agonist combinations that stimulate Th type I polarizing responses from human neonates</article-title>. <source>Innate Immun.</source><volume>24</volume>, <fpage>240</fpage>&#8211;<lpage>251</lpage>. doi: <pub-id pub-id-type="doi">10.1177/1753425918771178</pub-id>, PMID: <pub-id pub-id-type="pmid">29673285</pub-id><pub-id pub-id-type="pmcid">PMC6830928</pub-id></mixed-citation></ref><ref id="ref110"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tajiri</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ito</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kawai</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kashii</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hayashi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Murayama</surname><given-names>A.</given-names></name><etal/></person-group>. (<year>2022</year>). <article-title>Direct-acting antivirals for hepatitis C virus-infected patients with hepatocellular carcinoma</article-title>. <source>World J. Hepatol.</source><volume>14</volume>, <fpage>1190</fpage>&#8211;<lpage>1199</lpage>. doi: <pub-id pub-id-type="doi">10.4254/wjh.v14.i6.1190</pub-id>, PMID: <pub-id pub-id-type="pmid">35978673</pub-id><pub-id pub-id-type="pmcid">PMC9258255</pub-id></mixed-citation></ref><ref id="ref111"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Takeda</surname><given-names>K.</given-names></name><name name-style="western"><surname>Akira</surname><given-names>S.</given-names></name></person-group> (<year>2005</year>). <article-title>Toll-like receptors in innate immunity</article-title>. <source>Int. Immunol.</source><volume>17</volume>, <fpage>1</fpage>&#8211;<lpage>14</lpage>. doi: <pub-id pub-id-type="doi">10.1093/intimm/dxh186</pub-id>, PMID: <pub-id pub-id-type="pmid">15585605</pub-id></mixed-citation></ref><ref id="ref112"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Takeuchi</surname><given-names>O.</given-names></name><name name-style="western"><surname>Takeda</surname><given-names>K.</given-names></name><name name-style="western"><surname>Hoshino</surname><given-names>K.</given-names></name><name name-style="western"><surname>Adachi</surname><given-names>O.</given-names></name><name name-style="western"><surname>Ogawa</surname><given-names>T.</given-names></name><name name-style="western"><surname>Akira</surname><given-names>S.</given-names></name></person-group> (<year>2000</year>). <article-title>Cellular responses to bacterial cell wall components are mediated through MyD88-dependent signaling cascades</article-title>. <source>Int. Immunol.</source><volume>12</volume>, <fpage>113</fpage>&#8211;<lpage>117</lpage>. doi: <pub-id pub-id-type="doi">10.1093/intimm/12.1.113</pub-id>, PMID: <pub-id pub-id-type="pmid">10607756</pub-id></mixed-citation></ref><ref id="ref113"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Taylor</surname><given-names>D. N.</given-names></name><name name-style="western"><surname>Treanor</surname><given-names>J. J.</given-names></name><name name-style="western"><surname>Strout</surname><given-names>C.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>C.</given-names></name><name name-style="western"><surname>Fitzgerald</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kavita</surname><given-names>U.</given-names></name><etal/></person-group>. (<year>2011</year>). <article-title>Induction of a potent immune response in the elderly using the TLR-5 agonist, flagellin, with a recombinant hemagglutinin influenza-flagellin fusion vaccine (VAX125, STF2.HA1 SI)</article-title>. <source>Vaccine</source><volume>29</volume>, <fpage>4897</fpage>&#8211;<lpage>4902</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.vaccine.2011.05.001</pub-id>, PMID: <pub-id pub-id-type="pmid">21596084</pub-id></mixed-citation></ref><ref id="ref114"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tran</surname><given-names>T. T.</given-names></name></person-group> (<year>2011</year>). <article-title>Immune tolerant hepatitis B: a clinical dilemma</article-title>. <source>Gastroenterol. Hepatol.</source><volume>7</volume>, <fpage>511</fpage>&#8211;<lpage>516</lpage>. PMID: <pub-id pub-id-type="pmid">22298987</pub-id><pub-id pub-id-type="pmcid">PMC3264935</pub-id></mixed-citation></ref><ref id="ref115"><mixed-citation publication-type="other"><person-group person-group-type="author"><collab id="coll3">U.S. Food and Drug Administration</collab></person-group> (<year>2023</year>). FDA Approves First Vaccine to Prevent Disease Caused by Chikungunya Virus. FDA News Release. Availavle at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fda.gov/news-events/press-announcements/fda-approves-first-vaccine-prevent-disease-caused-chikungunya-virus" ext-link-type="uri">https://www.fda.gov/news-events/press-announcements/fda-approves-first-vaccine-prevent-disease-caused-chikungunya-virus</ext-link> (Accessed 15 Novemver 2023).</mixed-citation></ref><ref id="ref116"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Van Dis</surname><given-names>E.</given-names></name><name name-style="western"><surname>Sogi</surname><given-names>K. M.</given-names></name><name name-style="western"><surname>Rae</surname><given-names>C. S.</given-names></name><name name-style="western"><surname>Sivick</surname><given-names>K. E.</given-names></name><name name-style="western"><surname>Surh</surname><given-names>N. H.</given-names></name><name name-style="western"><surname>Leong</surname><given-names>M. L.</given-names></name><etal/></person-group>. (<year>2018</year>). <article-title>STING-activating adjuvants elicit a Th17 immune response and protect against <italic toggle="yes">Mycobacterium tuberculosis</italic> infection</article-title>. <source>Cell Rep.</source><volume>23</volume>, <fpage>1435</fpage>&#8211;<lpage>1447</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.celrep.2018.04.003</pub-id>, PMID: <pub-id pub-id-type="pmid">29719256</pub-id><pub-id pub-id-type="pmcid">PMC6003617</pub-id></mixed-citation></ref><ref id="ref117"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Van Hoeven</surname><given-names>N.</given-names></name><name name-style="western"><surname>Wiley</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gage</surname><given-names>E.</given-names></name><name name-style="western"><surname>Fiore-Gartland</surname><given-names>A.</given-names></name><name name-style="western"><surname>Granger</surname><given-names>B.</given-names></name><name name-style="western"><surname>Gray</surname><given-names>S.</given-names></name><etal/></person-group>. (<year>2018</year>). <article-title>A combination of TLR-4 agonist and saponin adjuvants increases antibody diversity and protective efficacy of a recombinant West Nile virus antigen</article-title>. <source>NPJ Vaccines</source><volume>3</volume>:<fpage>39</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41541-018-0077-1</pub-id>, PMID: <pub-id pub-id-type="pmid">30302281</pub-id><pub-id pub-id-type="pmcid">PMC6158298</pub-id></mixed-citation></ref><ref id="ref118"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vreman</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mccaffrey</surname><given-names>J.</given-names></name><name name-style="western"><surname>Popma-De Graaf</surname><given-names>D. J.</given-names></name><name name-style="western"><surname>Nauwynck</surname><given-names>H.</given-names></name><name name-style="western"><surname>Savelkoul</surname><given-names>H. F. J.</given-names></name><name name-style="western"><surname>Moore</surname><given-names>A.</given-names></name><etal/></person-group>. (<year>2019</year>). <article-title>Toll-like receptor agonists as adjuvants for inactivated porcine reproductive and respiratory syndrome virus (PRRSV) vaccine</article-title>. <source>Vet. Immunol. Immunopathol.</source><volume>212</volume>, <fpage>27</fpage>&#8211;<lpage>37</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.vetimm.2019.04.008</pub-id>, PMID: <pub-id pub-id-type="pmid">31213249</pub-id></mixed-citation></ref><ref id="ref119"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>K.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zou</surname><given-names>Z.</given-names></name><etal/></person-group>. (<year>2014</year>). <article-title>Immunizations with hepatitis B viral antigens and a TLR7/8 agonist adjuvant induce antigen-specific immune responses in HBV-transgenic mice</article-title>. <source>Int. J. Infect. Dis.</source><volume>29</volume>, <fpage>31</fpage>&#8211;<lpage>36</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.ijid.2014.07.015</pub-id><pub-id pub-id-type="pmid">25449231</pub-id><pub-id pub-id-type="pmcid">PMC4397646</pub-id></mixed-citation></ref><ref id="ref120"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Z. B.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>J.</given-names></name></person-group> (<year>2020</year>). <article-title>Better adjuvants for better vaccines: Progress in adjuvant delivery systems, modifications, and adjuvant-antigen Codelivery</article-title>. <source>Vaccines</source><volume>8</volume>:<fpage>128</fpage>. doi: <pub-id pub-id-type="doi">10.3390/vaccines8010128</pub-id><pub-id pub-id-type="pmid">32183209</pub-id><pub-id pub-id-type="pmcid">PMC7157724</pub-id></mixed-citation></ref><ref id="ref121"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ward</surname><given-names>B. J.</given-names></name><name name-style="western"><surname>Gobeil</surname><given-names>P.</given-names></name><name name-style="western"><surname>Seguin</surname><given-names>A.</given-names></name><name name-style="western"><surname>Atkins</surname><given-names>J.</given-names></name><name name-style="western"><surname>Boulay</surname><given-names>I.</given-names></name><name name-style="western"><surname>Charbonneau</surname><given-names>P. Y.</given-names></name><etal/></person-group>. (<year>2021</year>). <article-title>Phase 1 randomized trial of a plant-derived virus-like particle vaccine for COVID-19</article-title>. <source>Nat. Med.</source><volume>27</volume>, <fpage>1071</fpage>&#8211;<lpage>1078</lpage>. doi: <pub-id pub-id-type="doi">10.1038/s41591-021-01370-1</pub-id><pub-id pub-id-type="pmid">34007070</pub-id><pub-id pub-id-type="pmcid">PMC8205852</pub-id></mixed-citation></ref><ref id="ref122"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weeratna</surname><given-names>R. D.</given-names></name><name name-style="western"><surname>Makinen</surname><given-names>S. R.</given-names></name><name name-style="western"><surname>Mccluskie</surname><given-names>M. J.</given-names></name><name name-style="western"><surname>Davis</surname><given-names>H. L.</given-names></name></person-group> (<year>2005</year>). <article-title>TLR agonists as vaccine adjuvants: comparison of CpG ODN and Resiquimod (R-848)</article-title>. <source>Vaccine</source><volume>23</volume>, <fpage>5263</fpage>&#8211;<lpage>5270</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.vaccine.2005.06.024</pub-id>, PMID: <pub-id pub-id-type="pmid">16081189</pub-id></mixed-citation></ref><ref id="ref123"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Whitaker</surname><given-names>J. A.</given-names></name><name name-style="western"><surname>Rouphael</surname><given-names>N. G.</given-names></name><name name-style="western"><surname>Edupuganti</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lai</surname><given-names>L.</given-names></name><name name-style="western"><surname>Mulligan</surname><given-names>M. J.</given-names></name></person-group> (<year>2012</year>). <article-title>Strategies to increase responsiveness to hepatitis B vaccination in adults with HIV-1</article-title>. <source>Lancet Infect. Dis.</source><volume>12</volume>, <fpage>966</fpage>&#8211;<lpage>976</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S1473-3099(12)70243-8</pub-id>, PMID: <pub-id pub-id-type="pmid">23174382</pub-id><pub-id pub-id-type="pmcid">PMC4141523</pub-id></mixed-citation></ref><ref id="ref124"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wicherska-Pawlowska</surname><given-names>K.</given-names></name><name name-style="western"><surname>Wrobel</surname><given-names>T.</given-names></name><name name-style="western"><surname>Rybka</surname><given-names>J.</given-names></name></person-group> (<year>2021</year>). <article-title>Toll-like receptors (TLRs), NOD-like receptors (NLRs), and RIG-I-like receptors (RLRs) in innate immunity. TLRs, NLRs, and RLRs ligands as immunotherapeutic agents for hematopoietic diseases</article-title>. <source>Int. J. Mol. Sci.</source><volume>22</volume>:<fpage>397</fpage>. doi: <pub-id pub-id-type="doi">10.3390/ijms222413397</pub-id>, PMID: <pub-id pub-id-type="pmid">34948194</pub-id><pub-id pub-id-type="pmcid">PMC8704656</pub-id></mixed-citation></ref><ref id="ref125"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wille-Reece</surname><given-names>U.</given-names></name><name name-style="western"><surname>Flynn</surname><given-names>B. J.</given-names></name><name name-style="western"><surname>Lore</surname><given-names>K.</given-names></name><name name-style="western"><surname>Koup</surname><given-names>R. A.</given-names></name><name name-style="western"><surname>Kedl</surname><given-names>R. M.</given-names></name><name name-style="western"><surname>Mattapallil</surname><given-names>J. J.</given-names></name><etal/></person-group>. (<year>2005</year>). <article-title>HIV gag protein conjugated to a toll-like receptor 7/8 agonist improves the magnitude and quality of Th1 and CD8+ T cell responses in nonhuman primates</article-title>. <source>Proc. Natl. Acad. Sci. U. S. A.</source><volume>102</volume>, <fpage>15190</fpage>&#8211;<lpage>15194</lpage>. doi: <pub-id pub-id-type="doi">10.1073/pnas.0507484102</pub-id>, PMID: <pub-id pub-id-type="pmid">16219698</pub-id><pub-id pub-id-type="pmcid">PMC1257732</pub-id></mixed-citation></ref><ref id="ref126"><mixed-citation publication-type="other"><person-group person-group-type="author"><collab id="coll4">World Health Organization</collab></person-group> (<year>2022</year>). Hepatitis B. Updated on 24 June 2022. Available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.who.int/news-room/fact-sheets/detail/hepatitis-b" ext-link-type="uri">https://www.who.int/news-room/fact-sheets/detail/hepatitis-b</ext-link> (Accessed 11 June 2023).</mixed-citation></ref><ref id="ref127"><mixed-citation publication-type="other"><person-group person-group-type="author"><collab id="coll5">World Health Organization (WHO)</collab></person-group> (<year>2022</year>). Hepatitis C. Updated on 24 2022. Available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.who.int/news-room/fact-sheets/detail/hepatitis-c" ext-link-type="uri">https://www.who.int/news-room/fact-sheets/detail/hepatitis-c</ext-link> (Accessed 12 April 2023).</mixed-citation></ref><ref id="ref128"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yan</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kuolee</surname><given-names>R.</given-names></name><name name-style="western"><surname>Tram</surname><given-names>K.</given-names></name><name name-style="western"><surname>Qiu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>G. B.</given-names></name><etal/></person-group>. (<year>2009</year>). <article-title>3&#8242;,5'-cyclic diguanylic acid elicits mucosal immunity against bacterial infection</article-title>. <source>Biochem. Biophys. Res. Commun.</source><volume>387</volume>, <fpage>581</fpage>&#8211;<lpage>584</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.bbrc.2009.07.061</pub-id>, PMID: <pub-id pub-id-type="pmid">19615973</pub-id></mixed-citation></ref><ref id="ref129"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>J. X.</given-names></name><name name-style="western"><surname>Tseng</surname><given-names>J. C.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>G. Y.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>C. F.</given-names></name><name name-style="western"><surname>Hong</surname><given-names>Y. R.</given-names></name><etal/></person-group>. (<year>2022</year>). <article-title>Recent advances in the development of toll-like receptor agonist-based vaccine adjuvants for infectious diseases</article-title>. <source>Pharmaceutics</source><volume>14</volume>:<fpage>423</fpage>. doi: <pub-id pub-id-type="doi">10.3390/pharmaceutics14020423</pub-id><pub-id pub-id-type="pmid">35214155</pub-id><pub-id pub-id-type="pmcid">PMC8878135</pub-id></mixed-citation></ref><ref id="ref130"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yin</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>W.</given-names></name><name name-style="western"><surname>Mallajosyula</surname><given-names>V.</given-names></name><name name-style="western"><surname>Bo</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>J.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>J.</given-names></name><etal/></person-group>. (<year>2023</year>). <article-title>A TLR7-nanoparticle adjuvant promotes a broad immune response against heterologous strains of influenza and SARS-CoV-2</article-title>. <source>Nat. Mater.</source><volume>22</volume>, <fpage>380</fpage>&#8211;<lpage>390</lpage>. doi: <pub-id pub-id-type="doi">10.1038/s41563-022-01464-2</pub-id>, PMID: <pub-id pub-id-type="pmid">36717665</pub-id><pub-id pub-id-type="pmcid">PMC9981462</pub-id></mixed-citation></ref><ref id="ref131"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yokota</surname><given-names>S.</given-names></name><name name-style="western"><surname>Okabayashi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Fujii</surname><given-names>N.</given-names></name></person-group> (<year>2010</year>). <article-title>The battle between virus and host: modulation of toll-like receptor signaling pathways by virus infection</article-title>. <source>Mediators Inflamm.</source><volume>2010</volume>:<fpage>184328</fpage>, <fpage>1</fpage>&#8211;<lpage>12</lpage>. doi: <pub-id pub-id-type="doi">10.1155/2010/184328</pub-id><pub-id pub-id-type="pmid">20672047</pub-id><pub-id pub-id-type="pmcid">PMC2903949</pub-id></mixed-citation></ref><ref id="ref132"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>R. Y.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>S. H.</given-names></name><name name-style="western"><surname>He</surname><given-names>C. B.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>R. R.</given-names></name><etal/></person-group>. (<year>2022</year>). <article-title>Adjuvant-protein conjugate vaccine with built-in TLR7 agonist on S1 induces potent immunity against SARS-CoV-2 and variants of concern</article-title>. <source>ACS Infect Dis</source><volume>8</volume>, <fpage>1367</fpage>&#8211;<lpage>1375</lpage>. doi: <pub-id pub-id-type="doi">10.1021/acsinfecdis.2c00259</pub-id>, PMID: <pub-id pub-id-type="pmid">35748575</pub-id></mixed-citation></ref><ref id="ref133"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Egelston</surname><given-names>C.</given-names></name><name name-style="western"><surname>Gagnon</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sui</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Belyakov</surname><given-names>I. M.</given-names></name><name name-style="western"><surname>Klinman</surname><given-names>D. M.</given-names></name><etal/></person-group>. (<year>2010</year>). <article-title>Using 3 TLR ligands as a combination adjuvant induces qualitative changes in T cell responses needed for antiviral protection in mice</article-title>. <source>J. Clin. Invest.</source><volume>120</volume>, <fpage>607</fpage>&#8211;<lpage>616</lpage>. doi: <pub-id pub-id-type="doi">10.1172/JCI39293</pub-id>, PMID: <pub-id pub-id-type="pmid">20101095</pub-id><pub-id pub-id-type="pmcid">PMC2811160</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>